Regulatory agencies including the FDA and EMA expect sponsors to demonstrate that container-closure systems and device materials do not introduce harmful chemicals into drug products or patients. Consequently, the quality of your extractables study design directly influences approval timelines and post-market safety commitments. Teams at Materials Metric work with clients across these industries to build studies that satisfy both scientific rigor and regulatory expectations.

Furthermore, the field has grown more complex as combination products, novel polymers, and biologic drug formulations multiply. In particular, biologics are sensitive to trace-level extractables that can trigger protein aggregation or immunogenic responses. Therefore, study design must account for material composition, drug product type, route of administration, and intended patient population — all before a single extraction begins.

Key Takeaways

• Extractables study design is the systematic plan for identifying and quantifying chemicals that migrate from materials under exaggerated extraction conditions.
• Study scope, solvent selection, extraction conditions, and analytical methods must align with regulatory guidance such as ISO 10993-18 Chemical Characterization.
• Analytical technique selection — including GC-MS Analysis, HPLC Analysis, and elemental analysis — determines the breadth of the chemical profile generated.
• Threshold-based risk frameworks, including Analytical Evaluation Thresholds (AET), guide which compounds require full toxicological evaluation.
• Early-stage material screening can prevent costly late-stage reformulation or regulatory delays.
• Method development and validation are inseparable from study design quality.

Extractables Study Design: a structured experimental plan that defines the materials to be tested, extraction solvents and conditions, analytical methods, acceptance criteria, and reporting framework used to identify and quantify all chemicals that a material can release under controlled, exaggerated conditions — prior to leachables assessment and regulatory submission.

Key fact: Extractables identified during container-closure or device characterization studies represent one of the leading root causes of late-stage drug product failures and regulatory deficiency letters in pharmaceutical development programs.

What Is Extractables Study Design and Why Does It Matter?

An extractables study design is the master plan that governs every scientific decision made before, during, and after an extraction experiment. It specifies which materials to test, what solvents to use, how long to extract, which analytical platforms to deploy, and what thresholds to apply. Without this plan, data gaps emerge — and regulators ask pointed questions during review.

Moreover, a poorly scoped study can miss whole chemical classes. For example, a study relying only on GC-MS Analysis may detect volatile and semi-volatile organics effectively but overlook non-volatile species, inorganic elements, or oligomers. Consequently, comprehensive study design demands multiple orthogonal analytical techniques working in parallel.

The Regulatory Landscape Driving Study Design Requirements

Several regulatory frameworks shape what a compliant extractables study design must include. The ISO 10993-18 Chemical Characterization standard provides detailed guidance for medical devices, covering material characterization, extraction conditions, and analytical evaluation thresholds. Meanwhile, ICH Q3E (anticipated guidance on extractables and leachables) and USP chapters such as USP General Chapter <232> Elemental Impurities guide pharmaceutical applications.

These frameworks share a common thread: the study must be designed to detect potential hazards at or below toxicologically relevant thresholds. Importantly, the analytical evaluation threshold (AET) is derived from the permitted daily exposure (PDE) and the daily dose of the product. Therefore, knowing the clinical use scenario before designing the study is non-negotiable.

How Study Design Connects to Patient Safety

Extractables data feeds directly into the safety risk assessment. Specifically, each identified compound undergoes toxicological evaluation to determine whether it poses a risk at expected exposure levels. Furthermore, the study design determines whether that toxicological picture is complete or has blind spots.

For biologic products, even trace quantities of extractables can cause product instability or immunogenicity. As a result, study design for biologics typically demands lower detection limits, broader solvent coverage, and more sensitive analytical methods than studies for small-molecule drugs. The Biocompatibility & Toxicity Testing framework integrates tightly with extractables findings to complete the risk picture.

How to Define the Scope of an Extractables Study Design

Scope definition is the single most consequential step in extractables study design. It answers: what gets tested, under what conditions, and to what analytical depth? Misjudging scope — either too narrow or unnecessarily broad — wastes resources and creates regulatory risk.

Notably, scope depends on the material’s function, the drug product’s route of administration, the patient population, and the duration of patient contact. For instance, a primary container in direct contact with an injectable biologic demands more exhaustive characterization than a secondary packaging component with no drug contact.

Defining Material and Component Boundaries

The first scoping decision involves identifying which materials and components to include. Container-closure systems may consist of multiple components: vials, stoppers, plungers, caps, and adhesive labels. Each component contributes its own chemical inventory. Therefore, teams must decide whether to test components individually, as assembled systems, or both.

In addition, medical device extractables and leachables programs face similar decisions for multi-material device assemblies. Tubing sets, films, adhesives, and coatings each require separate consideration. Our article on extractables vs leachables explains the key conceptual distinction that guides component selection.

Selecting Appropriate Extraction Solvents

Solvent selection critically influences which extractables a study will detect. Regulatory guidance recommends using solvents that represent the range of drug product polarity — typically aqueous, organic, and acidic or basic media. Furthermore, solvents should be chosen to maximize extraction efficiency, not just mimic the drug product matrix.

Common solvent systems include water, isopropyl alcohol (IPA), hexane, methanol, and simulated drug product formulations. However, for parenteral or ophthalmic products, physiologically relevant extracting media (such as saline or phosphate-buffered saline) may also apply. As a result, many studies run three to five solvent systems in parallel to capture the full chemical profile. The extraction conditions article on our site explores this topic in greater depth.

Setting Extraction Time and Temperature Parameters

Extraction conditions are deliberately exaggerated beyond real-use scenarios. This exaggeration ensures the study identifies the worst-case chemical inventory — not just what leaches under normal storage. Specifically, accelerated conditions such as elevated temperature (e.g., 40°C or 70°C) and extended contact time push extractables levels well above those expected in actual product contact.

Moreover, exhaustive extraction approaches use reflux or repeated extractions until extractable levels plateau, ensuring that the study captures essentially all mobile chemical species. The choice between exaggerated and exhaustive extraction depends on the regulatory pathway, product type, and risk level assigned to the material.

Which Analytical Methods Should an Extractables Study Design Include?

Analytical method selection defines the chemical classes your study can detect and quantify. No single technique covers all possible extractables. Therefore, extractables study design routinely combines multiple complementary platforms to achieve broad chemical coverage.

Furthermore, the chosen methods must be sensitive enough to detect analytes at or below the AET. Method development and validation must precede sample analysis — an often underestimated workload in study planning. The team at Method Development & Validation can establish fit-for-purpose methods tailored to your specific material and product type.

Chromatographic Techniques for Organic Extractables

Gas chromatography–mass spectrometry remains the primary tool for volatile and semi-volatile organic extractables. GC-MS Analysis provides excellent sensitivity and library-based compound identification for compounds such as antioxidants, plasticizers, monomers, and processing aids. Headspace GC-MS additionally captures highly volatile species that would otherwise evaporate during sample preparation.

For non-volatile and polar compounds, HPLC Analysis coupled with UV, fluorescence, or mass spectrometric detection is the preferred approach. In particular, LC-MS/MS delivers high sensitivity for oligomers, surfactants, UV stabilizers, and other polar extractables that GC-MS cannot efficiently analyze. Together, GC-MS and LC-MS provide the core organic extractables profile in most regulatory submissions.

Spectroscopic Techniques for Structural Confirmation

Chromatography separates and quantifies compounds, but spectroscopic tools confirm their identity and structure. FTIR Analysis rapidly identifies functional groups and polymer classes in bulk material characterization. Meanwhile, NMR Spectroscopy provides definitive structural elucidation for unknown extractables that mass spectral library matching cannot fully resolve.

In addition, Raman Spectroscopy complements FTIR analysis for materials that absorb strongly in the infrared range, such as aqueous solutions or black-pigmented polymers. Consequently, the combination of chromatographic separation and spectroscopic confirmation builds a defensible identification record for each detected compound.

Elemental Analysis for Inorganic Extractables

Inorganic extractables — including heavy metals and catalyst residues — require dedicated elemental analysis platforms. Specifically, inductively coupled plasma mass spectrometry (ICP-MS) and inductively coupled plasma optical emission spectrometry (ICP-OES) deliver the sub-ppb detection limits required for compliance with USP General Chapter <232> Elemental Impurities and ICH Q3D.

Furthermore, XRF Analysis serves as a rapid bulk-screening tool to flag materials with high concentrations of elements of concern before solution-based ICP analysis. Meanwhile, XPS Analysis characterizes surface elemental composition — particularly useful when surface treatments or coatings are a known source of extractables. A full Chemical & Elemental Characterization program typically integrates several of these techniques.

Comparison of Core Analytical Techniques in Extractables Study Design

Quick note: Many extractables study design failures stem not from poor analysis, but from inadequate study scoping at the planning stage. Defining material boundaries, solvent systems, extraction conditions, and AETs before any lab work begins is the most cost-effective investment a development team can make.

Comprehensive Chemical & Analytical Testing integrates these platforms into a single coordinated extractables program. This integration prevents data gaps and reduces turnaround time by running orthogonal techniques in parallel rather than sequentially. For complex materials, Scientific & Technical Consulting services help teams make defensible method and technique selection decisions before study initiation.

Additionally, Chemical Purity & Contaminant Screening capabilities support early-phase material qualification, where the goal is rapid identification of high-risk chemical species before committing to a full extractables program. For background on published analytical method strategies, ScienceDirect – Analytical Methods provides an extensive peer-reviewed resource base that study designers frequently consult.

How to Apply the Analytical Evaluation Threshold in Extractables Study Design

The Analytical Evaluation Threshold (AET) is the quantitative cornerstone of every extractables study design. It defines the minimum concentration at which a detected compound must be identified and reported. Consequently, the AET drives analytical method sensitivity requirements and instrument selection.

Teams calculate the AET from the permitted daily exposure (PDE) of a compound, the maximum daily dose of the product, and a safety factor. Specifically, a compound detected below the AET requires no further toxicological evaluation. However, any compound at or above the AET demands full identification, quantification, and toxicological assessment.

Calculating the AET for Your Product Type

AET calculation begins with the product’s clinical use parameters. These include the maximum daily dose volume, the number of doses per day, and the number of container components in contact with the drug. For instance, a low-dose injectable may produce a higher AET (less stringent detection requirement) than a high-volume infusion product administered repeatedly.

Furthermore, the calculation uses a default threshold of 0.1 μg/day as the toxicological concern threshold (TTC) for unknown compounds, per ICH M7 principles adapted into extractables guidance. Therefore, analytical methods must reliably detect and quantify compounds at concentrations that correspond to the product-specific AET — often in the low-ppb range.

Applying AET Across Multiple Solvent Systems

Each extraction solvent generates its own set of extract concentrations. Importantly, the AET applies to each solvent extract independently, adjusted for the extraction ratio used. Moreover, when multiple solvents are run in parallel, teams must track AET compliance separately for aqueous, organic, and acidic or basic extracts.

As a result, study planners often tabulate AET values for each solvent system before lab work begins. This table becomes a critical quality control document, guiding analysts on which peaks to report and which to discard as below threshold. Our Method Development & Validation team routinely assists clients in establishing and documenting these thresholds as part of the study protocol.

Industry-Specific Applications of Extractables Study Design

Extractables study design is not a one-size-fits-all discipline. The specific requirements shift substantially depending on the industry, product type, regulatory jurisdiction, and patient population involved. Understanding these differences is essential before finalizing any study protocol.

Moreover, some industries operate under overlapping regulatory frameworks, requiring study designers to satisfy multiple guidance documents simultaneously. In those cases, Scientific & Technical Consulting services help resolve conflicts and identify the most efficient path to compliance.

Pharmaceutical and Biologic Drug Products

Pharmaceutical programs typically follow ICH Q3E, ICH Q3D, USP <661>, USP <1663>, and USP <1664> guidance. Biologic drug products — including monoclonal antibodies, gene therapies, and cell therapies — face the most stringent extractables requirements. Specifically, even sub-ppb concentrations of certain extractables can destabilize protein structures or trigger immunogenic responses.

Therefore, extractables study design for biologics demands ultra-sensitive detection limits, extensive solvent coverage, and careful attention to oxidative and metal-ion extractables. Integrating Biocompatibility & Toxicity Testing data with the extractables chemical profile provides a complete safety picture for regulatory submission.

Medical Devices and Combination Products

Medical device programs operate primarily under ISO 10993-18 for chemical characterization. This standard requires a structured approach: material identification, chemical characterization, biological risk assessment, and clinical exposure estimation. Notably, combination products — devices that contain a drug component — must satisfy both pharmaceutical and device regulatory requirements simultaneously.

In addition, device materials often include multiple polymer types, adhesives, coatings, and metals. Each material class requires different extraction solvents and analytical platforms. Consequently, device extractables programs frequently run larger test matrices than pharmaceutical container-closure studies. Our published resource on medical device extractables and leachables details the device-specific regulatory and analytical landscape.

Aerospace, Industrial, and Environmental Applications

Beyond pharma and medical devices, extractables study design principles apply wherever material-chemical interactions affect safety or performance. Aerospace programs evaluate polymers, sealants, and coatings for outgassing behavior and chemical release under vacuum or elevated temperature conditions. Similarly, environmental programs assess extractables from plastic packaging, water treatment membranes, and food-contact materials.

Furthermore, industrial quality programs use extraction studies to qualify raw materials, detect counterfeit substances, and monitor supplier consistency. The Chemical & Analytical Testing capabilities at Materials Metric serve all of these sectors, applying the same rigorous extractables study design principles regardless of industry context.

Industry-Specific Study Design Requirements Comparison

Quality Assurance and Best Practices in Extractables Study Design

Rigorous quality assurance practices distinguish a defensible extractables study from one that generates regulatory questions. Every element of the study — from sample chain of custody to instrument calibration — must be documented and traceable. Moreover, studies conducted under Good Laboratory Practice (GLP) conditions provide the highest level of regulatory confidence.

However, even non-GLP studies benefit significantly from systematic quality controls. Spike recovery experiments, method blanks, reagent blanks, and certified reference standards all contribute to data reliability. For background on published best practices, ScienceDirect hosts extensive peer-reviewed literature on analytical quality assurance methodologies.

Protocol Development and Change Control

A written extractables study protocol must be finalized and approved before sample preparation begins. This protocol locks in all critical parameters: sample identification, extraction conditions, solvent systems, analytical methods, acceptance criteria, and reporting thresholds. Importantly, any mid-study deviation requires documented justification and impact assessment.

Furthermore, change control procedures protect data integrity when equipment, reagents, or personnel change during a study. Consequently, teams that invest in thorough upfront protocol development avoid the costly and time-consuming amendment process. The Method Development & Validation framework at Materials Metric embeds these quality controls into every extractables program from day one.

Reference Standards and Spike Recovery

Reference standards are essential for compound identification and quantification accuracy. Specifically, certified reference materials allow analysts to confirm instrument response, validate retention times, and establish calibration curves across the working concentration range. Additionally, isotopically labeled internal standards — used in ICP-MS and LC-MS/MS — correct for matrix suppression effects and improve quantitative accuracy.

Spike recovery experiments verify that the extraction process and analytical workflow recover target analytes efficiently. Acceptable spike recovery typically falls between 70% and 130% for most extractables applications. As a result, poor spike recovery indicates a matrix interference or method problem that must be resolved before reporting study results. The Chemical & Elemental Characterization team at Materials Metric routinely applies these controls across all elemental and organic extractables programs.

Reporting, Documentation, and Regulatory Package Readiness

Study reports must present extractables data in a format that directly supports the safety risk assessment and regulatory submission. Typically, this means organized compound tables with chemical identity, CAS number, concentration, detection method, and AET comparison. Furthermore, chromatograms, spectra, calibration curves, and raw instrument data should be archived and available for regulatory inspection.

Additionally, USP Elemental Impurities guidance requires that elemental extractables data be traceable to specific container components and presented against established PDEs. Ultimately, a well-documented extractables study report functions as a standalone scientific document — one that regulators can evaluate independently of the broader submission dossier.

Quick note: Regulatory reviewers frequently request raw data, instrument logs, and reference standard certificates during extractables data audits. Archiving these documents in a retrievable, organized format from day one — not as an afterthought — saves significant time during agency interactions.

Frequently Asked Questions About Extractables Study Design

What is the difference between extractables and leachables?

Extractables are chemicals released from a material under exaggerated laboratory conditions using aggressive solvents and elevated temperatures. Leachables, by contrast, are compounds that actually migrate into the drug product or patient under real-use conditions. Consequently, extractables studies generate a worst-case chemical inventory, while leachables studies confirm what actually transfers in practice. Our article on extractables vs leachables provides a detailed breakdown of this distinction.

When should an extractables study design be initiated?

Ideally, extractables study design begins during early-stage material selection — well before the drug product formulation or device design is locked. Starting early allows teams to reject high-risk materials before significant development investment occurs. Moreover, early extractables data supports informed decisions about container-closure system changes, supplier qualification, and formulation compatibility.

How many solvents does a typical extractables study require?

Most regulatory guidance recommends a minimum of three extraction solvents covering a range of polarity: an aqueous solvent, an organic solvent, and an acidic or basic medium. However, more complex materials — such as multi-layer films or silicone-based medical device components — may require four to six solvents to adequately cover all chemical classes present. Additionally, simulated drug product formulations are sometimes included as a fourth extraction medium.

What analytical techniques are most commonly used in extractables studies?

The most widely used techniques include GC-MS Analysis for volatile and semi-volatile organics, HPLC Analysis (LC-MS/MS) for non-volatile polar compounds, and ICP-MS or ICP-OES for elemental impurities. Furthermore, NMR Spectroscopy and FTIR Analysis support structural confirmation of unknown compounds. The specific technique combination depends on the material type, product application, and regulatory pathway.

Does an extractables study need to be conducted under GLP conditions?

GLP compliance is not universally required for extractables studies, but it is often expected for studies supporting regulatory submissions in high-risk product categories. Specifically, studies submitted as part of an NDA, BLA, or PMA application benefit from GLP rigor, which provides auditable documentation and enhanced regulatory credibility. Nevertheless, even non-GLP studies must follow robust quality controls to produce scientifically defensible data.

How does extractables study design support leachables risk assessment?

The extractables chemical inventory serves as the predicted leachables list. Toxicologists use this list to prioritize which compounds require formal safety qualification if they appear in the drug product. Specifically, compounds identified above the AET in extraction studies become candidates for leachables monitoring in real-use samples. Therefore, a comprehensive extractables study design directly reduces the scope of uncertainty in the downstream leachables and safety evaluation process.

Conclusion

A rigorous extractables study design is the scientific and regulatory foundation that supports every downstream safety assessment, leachables program, and regulatory submission. Getting the design right — from scope definition and solvent selection to AET calculation and analytical method coverage — determines whether a product advances confidently through development or encounters costly delays.

Furthermore, the field continues to evolve as new materials, biologic drug formats, and regulatory guidance documents emerge. Consequently, study designers must stay current with ICH, ISO, and USP updates while applying fit-for-purpose analytical strategies that match the specific risk profile of each product. The investment in a well-constructed extractables study design repays itself many times over by preventing late-stage surprises.

Moreover, partnering with an experienced analytical laboratory ensures that your extractables program integrates the right techniques, applies correct thresholds, and produces documentation that regulators accept with confidence. From early material screening through final submission support, the team at Materials Metric delivers coordinated extractables programs across pharmaceutical, medical device, and industrial sectors.

If your team is planning an extractables program — or needs to rescue a study with data gaps — contact Materials Metric today to discuss your specific materials, product type, and regulatory requirements with our analytical and regulatory specialists.

Related Posts from Materials Metric

Explore more insights from our team of materials scientists and analytical experts:

• Chemical characterization cost | Materials Metric | Chem Lab
• Combination product characterization | Materials Metric
• Non-targeted analysis | Materials Metric | Chem Lab
• Unknown compound identification | Materials Metric

The post Extractables study design | Materials Metric | Chem Lab appeared first on Comprehensive Materials Testing and Analytical Services at Materials Metric.

Combination product characterization is the systematic process of identifying, analyzing, and documenting the chemical, physical, and biological properties of products that integrate a drug, device, and/or biological component into a single regulated entity. At Materials Metric, we help manufacturers navigate this complex testing landscape with confidence and regulatory clarity.

Regulatory agencies such as the FDA require thorough characterization data before approving any combination product. Consequently, manufacturers must address each constituent part — the drug substance, the device material, and any biological component — both individually and as a combined system. Without this data, submissions risk rejection or costly remediation cycles.

Furthermore, combination product characterization encompasses far more than simple chemical analysis. It integrates extractables and leachables profiling, biocompatibility evaluation, elemental impurity screening, and material identification into one coherent evidence package. As a result, the testing strategy must be carefully designed from the earliest stages of product development.

Key Takeaways

• Combination products contain a drug, device, and/or biological component — each requiring dedicated characterization testing.
• Regulatory frameworks from the FDA, ISO, and USP govern how manufacturers must characterize these products.
• A well-designed characterization strategy covers chemistry, materials, extractables, leachables, and biocompatibility.
• Early-stage testing reduces costly late-development surprises and supports faster regulatory approval.
• Third-party laboratories provide independent, audit-ready data to strengthen regulatory submissions.

Combination product characterization: the comprehensive analytical and scientific evaluation of a product that combines drug, device, and/or biological components, conducted to identify material composition, chemical interactions, extractable and leachable substances, and biological safety risks in order to meet regulatory approval requirements.

Key fact: The FDA Office of Combination Products reports that combination products represent one of the fastest-growing and most complex product categories in the medical device and pharmaceutical industries, making robust characterization one of the leading drivers of regulatory submission quality.

What Defines a Combination Product Under Regulatory Frameworks?

Understanding what qualifies as a combination product is essential before building any characterization strategy. The FDA defines a combination product under 21 CFR Part 3 as a product comprising two or more regulated components — drug/device, drug/biologic, device/biologic, or all three — that are physically, chemically, or otherwise combined into a single entity.

The Three Main Combination Product Categories

Prefilled syringes are among the most commonly encountered examples in the industry. Additionally, drug-eluting stents, autoinjectors, and transdermal drug delivery patches all fall within this category. Each product type presents a distinct set of characterization challenges based on how the components interact.

Moreover, co-packaged products — where a device and drug are packaged together but used separately — also require combination product registration. For example, a surgical kit containing a topical drug and applicator device demands a coordinated review strategy. Therefore, manufacturers must map the constituent parts accurately before scoping their characterization work.

By contrast, cross-labeled products involve separately manufactured components with labeling that references the other component. Consequently, even without physical integration, regulators may require a unified characterization data package. Understanding the product type early helps define the testing scope precisely.

Primary Mode of Action and Lead Center Assignment

The FDA assigns combination products to a lead center — CDER, CDRH, or CBER — based on the product’s primary mode of action (PMOA). Specifically, if the drug component drives the primary therapeutic effect, CDER takes the lead. In addition, CDRH leads when the device component is the primary driver.

This assignment matters significantly for characterization. Furthermore, the lead center determines which regulatory pathways, guidances, and standards apply. For instance, CDRH-led products typically require ISO 10993 biocompatibility testing, while CDER-led products must satisfy USP and ICH requirements for drug substance and container-closure integrity.

Manufacturers should therefore request a Designation Request from the FDA’s Office of Combination Products when the PMOA is unclear. Doing so early avoids costly mid-development changes to the testing strategy. Overall, clarity on regulatory jurisdiction streamlines every subsequent characterization decision.

Why Is Combination Product Characterization Scientifically Challenging?

Combination product characterization poses unique scientific challenges precisely because no single regulatory framework fully covers all constituent components. Unlike a standalone medical device or a drug product, a combination product requires the simultaneous application of pharmaceutical chemistry, materials science, and toxicology expertise.

Material Interactions and Chemical Complexity

When a drug contacts a device component, new chemical interactions can occur. For example, plasticizers, adhesives, colorants, and processing aids in polymer-based device components may migrate into the drug substance over time. Consequently, this migration can alter drug potency, create new impurities, or introduce toxic leachables into the patient dose.

Furthermore, the drug formulation itself can affect device materials. Organic solvents in drug solutions may swell or degrade certain elastomers, altering extractable profiles significantly. Therefore, characterization must evaluate the drug-device interface under realistic, worst-case storage and use conditions.

Analytical tools such as GC-MS Analysis and HPLC Analysis are essential for identifying and quantifying these migrating chemical species. In addition, FTIR Analysis provides material identification data that helps trace the source of unexpected chemical signals. Together, these techniques build a robust chemical picture of the product system.

Biological Safety Considerations Unique to Combination Products

Combination products often involve prolonged or intimate patient contact, raising the stakes for biocompatibility evaluation. Importantly, the ISO 10993 series — specifically ISO 10993-18 Chemical Characterization — requires a chemistry-based risk assessment before any in vivo testing. This chemical characterization step is therefore central to the entire biological evaluation process.

In addition, toxicological risk assessment (TRA) requires comparing identified leachables against established threshold of toxicological concern (TTC) values. When leachables exceed TTC limits, additional biological testing becomes necessary. Consequently, early chemical characterization data directly controls the scope and cost of subsequent biocompatibility studies.

Materials Metric’s Biocompatibility & Toxicity Testing services are specifically designed to address these compound challenges. Furthermore, our team integrates chemical characterization findings with toxicological risk assessments to produce complete, submission-ready biological evaluation reports. This integrated approach saves manufacturers significant time and resources.

Regulatory Overlap and Dual Compliance Requirements

One of the most difficult aspects of combination product characterization involves satisfying two or more regulatory frameworks simultaneously. For instance, a prefilled autoinjector must comply with both ICH Q3D elemental impurity requirements for drugs and ISO 10993-18 chemical characterization requirements for the device container. These two standards use different analytical thresholds and risk assessment methodologies.

Additionally, USP requirements — such as USP General Chapter <232> Elemental Impurities — must be addressed for any drug-containing combination product. However, the device component may introduce elemental impurities through entirely different pathways than typical drug manufacturing. Therefore, a single unified analytical strategy must bridge both frameworks efficiently.

Manufacturers benefit greatly from working with a laboratory that understands both pharmaceutical and device regulatory contexts. Specifically, Scientific & Technical Consulting from experienced analytical chemists can map the applicable standards to the actual product design. Overall, this planning step prevents redundant testing and closes compliance gaps before they become regulatory issues.

What Analytical Methods Support Combination Product Characterization?

Effective combination product characterization depends on deploying the right analytical techniques in the right sequence. No single method captures all the required data. Instead, a well-designed testing battery combines spectroscopic, chromatographic, microscopic, and thermal techniques to build a complete material and chemical profile.

Spectroscopic Techniques for Material Identification

Spectroscopic methods form the backbone of any combination product characterization program. FTIR Analysis identifies polymer types, functional groups, and contaminants on material surfaces with high specificity. In addition, Raman Spectroscopy complements FTIR by analyzing aqueous samples and thin films that challenge infrared techniques.

Furthermore, XPS Analysis provides detailed surface chemistry data — particularly useful for coated device components in drug-device combinations. Similarly, XRF Analysis delivers rapid, non-destructive elemental screening across a wide range of materials. Together, these tools provide a multi-layered view of the product’s material composition.

Chromatographic Methods for Chemical Purity and Leachables

Chromatographic techniques are indispensable for extractables and leachables profiling. GC-MS Analysis excels at detecting and identifying volatile and semi-volatile organic compounds in device extracts. Meanwhile, HPLC Analysis covers non-volatile and polar compounds that GC-MS cannot resolve effectively.

In particular, NMR Spectroscopy offers powerful structural elucidation for unknown leachable compounds identified by chromatographic screening. Consequently, NMR is frequently used to confirm peak identities and support toxicological risk assessments with confident structural data. This confirmation step is critical when leachables approach or exceed safety thresholds.

For elemental impurities, inductively coupled plasma mass spectrometry (ICP-MS) and ICP-OES provide the sensitivity and selectivity required by ICH Q3D and USP General Chapter <232>. Moreover, our Chemical Purity & Contaminant Screening services cover these elemental techniques alongside organic impurity analysis. As a result, manufacturers receive a complete impurity profile from a single laboratory partner.

Microscopic and Structural Analysis Techniques

Physical characterization of combination product materials requires high-resolution microscopic techniques. SEM Analysis reveals surface morphology, particulate contamination, and interface characteristics at the micron scale. Furthermore, energy-dispersive X-ray spectroscopy (EDS) coupled with SEM provides localized elemental mapping of those features.

For crystalline materials in drug-device combinations, XRD Analysis confirms phase composition and polymorph identity. Additionally, DSC Testing characterizes thermal transitions such as melting points, glass transition temperatures, and crystallinity — all of which influence drug release and device performance. These thermal and structural data points are increasingly required in regulatory submissions for combination products.

Quick note: A well-scoped analytical test plan for combination product characterization typically includes at least four to six complementary techniques spanning spectroscopy, chromatography, microscopy, and thermal analysis. Using a single method in isolation risks missing critical chemical interactions or impurities that only emerge through orthogonal approaches.

Our Chemical & Elemental Characterization services integrate all of these techniques into a single coordinated program. Specifically, we align method selection with the applicable regulatory frameworks — ISO 10993-18, ICH Q3D, and USP — to ensure the data fully supports the submission. Furthermore, our Chemical & Analytical Testing capabilities allow us to execute the full characterization battery under one quality system, simplifying data traceability and audit management.

By comparison, using multiple disconnected laboratories for different analytical techniques creates coordination risks and data integrity challenges. Therefore, working with a single expert partner for the full combination product characterization scope offers significant practical and regulatory advantages.

Moreover, early engagement with the analytical laboratory during product design allows the testing strategy to evolve alongside the design. Consequently, last-minute testing surprises — which are a leading cause of submission delays — become far less likely when characterization is built into the development timeline from the start.

How Does Elemental Impurity Testing Fit Into Combination Product Characterization?

Elemental impurity testing plays a central role in combination product characterization. Residual metals from device components, processing equipment, and raw materials can migrate into the drug product and harm patients. Therefore, manufacturers must apply a structured, risk-based analytical approach that satisfies both pharmaceutical and device standards simultaneously.

ICP-MS and ICP-OES: The Gold Standards for Elemental Analysis

Inductively coupled plasma mass spectrometry (ICP-MS) delivers exceptional sensitivity for elemental impurity detection. Specifically, ICP-MS can quantify elements at parts-per-trillion (ppt) levels — a critical capability when oral daily exposure (ODE) limits are extremely tight. Consequently, this technique is the preferred tool for meeting ICH Q3D and USP Elemental Impurities requirements in drug-containing combination products.

Inductively coupled plasma optical emission spectrometry (ICP-OES) complements ICP-MS for higher-concentration elemental work. Furthermore, ICP-OES handles complex matrices more robustly in some scenarios, making it ideal for device component digests. Together, these two techniques cover the full periodic table of concern across both pharmaceutical and device constituent parts.

Atomic Absorption Spectrometry as a Targeted Method

Atomic absorption spectrometry (AAS) offers a cost-effective, targeted approach for specific elemental analyses. For example, graphite furnace AAS (GFAAS) achieves excellent detection limits for elements such as lead, cadmium, and arsenic. However, AAS analyzes only one element per run, making it less efficient than ICP-MS for broad-spectrum screening programs.

Manufacturers often use AAS to confirm ICP-MS findings for specific elements of regulatory concern. Additionally, AAS serves as a validation reference method when developing ICP-based procedures. Overall, a combination of ICP-MS, ICP-OES, and AAS provides comprehensive elemental coverage for any combination product characterization program.

Linking Elemental Data to Toxicological Risk Assessment

Raw elemental concentration data alone does not satisfy regulatory requirements. Moreover, manufacturers must convert those concentrations into patient daily exposures and compare them against ICH Q3D permitted daily exposures (PDEs). Consequently, the laboratory must understand route-of-administration adjustments and the specific contact duration of the combination product.

Our Chemical & Elemental Characterization services include not only analytical measurement but also expert interpretation aligned with regulatory limits. Furthermore, our team integrates elemental findings into the broader toxicological risk assessment required by ISO 10993-18. This end-to-end approach ensures that analytical data translates directly into defensible regulatory conclusions.

Combination Product Characterization Across Key Industry Applications

Combination product characterization requirements vary considerably depending on the product type and its intended clinical use. Understanding industry-specific expectations helps manufacturers scope testing efficiently and avoid both under-testing and over-testing. The following sections outline the most common application areas and their distinct characterization demands.

Drug-Device Combinations in Pharmaceutical Development

Prefilled syringes, autoinjectors, and inhaled drug-device systems represent the largest category of pharmaceutical combination products. In particular, container-closure integrity, extractables and leachables profiling, and elemental impurity testing are all mandatory for these systems. Furthermore, drug compatibility studies must confirm that device materials do not degrade the active pharmaceutical ingredient over the product shelf life.

Published research in ScienceDirect analytical journals consistently highlights how multi-technique characterization strategies improve confidence in drug-device compatibility conclusions. Specifically, combining GC-MS, HPLC, and ICP-MS data provides a far more complete picture than any single technique alone. Our Chemical & Analytical Testing services are structured precisely to support this multi-technique approach.

Implantable and Long-Term Contact Medical Devices With Drug Components

Drug-eluting stents, drug-coated orthopedic implants, and intravitreal drug delivery systems involve extended or permanent patient contact. As a result, biocompatibility requirements are among the most stringent in the combination product space. Specifically, ISO 10993 testing must cover cytotoxicity, sensitization, systemic toxicity, and implantation — all informed by chemistry data.

Additionally, the extended contact duration amplifies leachable exposure risks significantly. Even low-concentration leachables become safety concerns when a patient is exposed continuously over years. Consequently, the analytical detection limits and toxicological risk thresholds applied to these products must reflect their unique exposure profiles.

Our Biocompatibility & Toxicity Testing team works closely with combination product developers to design studies that address these extended-exposure scenarios comprehensively. Moreover, we integrate chemical characterization data with biological evaluation findings into a single coherent regulatory package.

Transdermal Delivery Systems and Topical Drug-Device Combinations

Transdermal patches combine adhesive device materials with drug reservoirs in intimate skin contact. Characterization for these products must address adhesive polymer extractables, drug permeation enhancer compatibility, and backing film leachables simultaneously. Therefore, the analytical scope is broader than for many other combination product types.

Furthermore, skin sensitization potential of leachables requires early assessment using toxicological risk analysis based on chemistry data. By identifying high-concern chemicals early, manufacturers can reformulate or substitute materials before clinical studies begin. This proactive approach significantly reduces late-stage development risk and regulatory uncertainty.

Building a Robust Quality Assurance Framework for Combination Product Characterization

Strong quality assurance practices underpin every reliable combination product characterization program. Regulatory agencies scrutinize not only the test results but also the systems that generated them. Consequently, manufacturers must ensure their laboratory partners operate under validated methods, traceable standards, and documented quality management systems.

Method Development and Validation for Combination Products

Standard pharmacopeial or compendial methods do not always exist for combination product characterization challenges. In many cases, laboratories must develop custom extraction procedures, tailored analytical methods, and product-specific sample preparation protocols. Therefore, method development and validation become critical steps before generating any regulatory submission data.

Validation parameters — including specificity, linearity, accuracy, precision, detection limit, and quantitation limit — must be formally demonstrated for each analytical method. Furthermore, validation must be conducted under a quality system that meets ICH Q2(R1) guidance. Our Method Development & Validation services ensure that every characterization method we employ generates data that regulators can rely on with confidence.

Documentation, Data Integrity, and Audit Readiness

Regulatory submissions for combination products require comprehensive, traceable documentation. Specifically, raw data, instrument logs, calibration records, and analyst training records must all be accessible and auditable. Additionally, data integrity principles — including ALCOA+ (Attributable, Legible, Contemporaneous, Original, Accurate) — apply to all generated characterization data.

Third-party laboratories with ISO 17025 accreditation provide an independent quality assurance layer that regulatory agencies recognize. Moreover, working with an accredited partner simplifies your audit preparation and demonstrates a commitment to scientific rigor. Our Scientific & Technical Consulting team can also help you design an internal documentation framework that aligns with FDA expectations for combination product submissions.

Establishing a Testing Timeline Aligned With Development Milestones

Timing characterization activities correctly prevents costly development delays. Importantly, extractables studies on device components should begin during early design stages, long before clinical material is committed. Consequently, any chemistry-driven material changes can occur before the design is locked — saving both time and money.

A phased testing approach works well for most combination product programs. Initially, broad screening studies identify the full chemical space of concern. Subsequently, targeted leachables studies under real-world conditions confirm actual patient exposure levels. Finally, toxicological risk assessments close the loop and define whether additional biological testing is required.

Quick note: Starting combination product characterization after design freeze significantly increases the risk of uncovering material incompatibilities too late to address without costly design changes or testing repeats. Engage your analytical laboratory partner at the earliest design stages possible.

Frequently Asked Questions About Combination Product Characterization

What is the difference between extractables and leachables in combination product characterization?

Extractables are chemical compounds that migrate from device or packaging materials under aggressive laboratory conditions — typically using exaggerated solvents, temperatures, or contact times. Leachables, by contrast, are the subset of those compounds that actually migrate into the drug product under normal storage and use conditions. Therefore, extractables studies define the worst-case chemical space, while leachables studies confirm real-world patient exposure.

Which regulatory standards govern combination product characterization?

Several overlapping standards apply, depending on the product type and lead regulatory center. Key frameworks include FDA 21 CFR Part 3 for classification, ISO 10993-18 for chemical characterization of device components, ICH Q3D for elemental impurities, and USP General Chapters <232> and <233> for elemental impurity testing in drugs. Furthermore, FDA guidance documents specifically addressing combination products — such as the 2016 Current Good Manufacturing Practice guidance — add additional compliance requirements.

When should combination product characterization testing begin during development?

Ideally, manufacturers should initiate extractables screening during the material selection and early design phase. Consequently, data from these early studies informs both material selection decisions and the risk assessment framework. Waiting until late-stage development or design freeze to begin characterization significantly increases the risk of expensive surprises that delay regulatory submission.

Can a single laboratory handle both pharmaceutical and device characterization requirements?

Yes — and working with a single expert partner offers significant advantages. Specifically, a laboratory experienced in both pharmaceutical and medical device analytical requirements can design a unified testing strategy that satisfies both regulatory frameworks simultaneously. Moreover, single-source testing simplifies data traceability, reduces coordination burden, and produces a coherent evidence package that is easier for regulators to review.

How does toxicological risk assessment (TRA) connect to chemical characterization data?

TRA uses the chemical identity and concentration data generated during characterization to calculate patient daily exposure for each identified leachable or impurity. Specifically, those exposures are then compared against established safety thresholds — such as the threshold of toxicological concern (TTC) or ICH Q3D permitted daily exposures. When exposure levels exceed thresholds, additional biological testing is triggered. Therefore, the quality and completeness of the chemical characterization data directly determines the scope and cost of the biological safety program.

What should manufacturers look for when selecting a combination product characterization laboratory?

Key selection criteria include ISO 17025 accreditation, demonstrated experience with both pharmaceutical and medical device standards, a broad suite of in-house analytical instrumentation, and validated methods for extractables and leachables profiling. Furthermore, the laboratory should offer toxicological risk assessment capabilities and regulatory consulting support. Importantly, a partner that can deliver integrated analytical and regulatory strategy — rather than just raw data — adds the greatest value to your development program.

Conclusion

Combination product characterization is one of the most technically demanding and regulatory-critical activities in modern pharmaceutical and medical device development. Successfully navigating it requires deep analytical expertise, a multi-technique testing strategy, and a thorough understanding of overlapping regulatory frameworks. Furthermore, it demands disciplined quality assurance and early integration into the product development timeline.

The consequences of inadequate characterization are significant. Regulatory submissions risk rejection, clinical studies may be delayed, and patient safety can be compromised when chemical interactions and leachable exposures go undetected. Therefore, investing in a rigorous, well-planned characterization program from the earliest development stages is both a scientific and a business imperative.

At Materials Metric, our team brings together analytical chemistry, materials science, and regulatory expertise to support every stage of your combination product characterization program. Specifically, we offer fully integrated services — from method development and extractables screening through elemental impurity testing and biocompatibility assessment — all under a single, audit-ready quality system. Moreover, our Method Development & Validation capabilities ensure that every data point we generate meets the evidentiary standards regulators expect.

Whether you are developing a prefilled autoinjector, a drug-eluting implant, or a transdermal delivery system, we have the instruments, expertise, and regulatory knowledge to support your characterization goals. Additionally, our Scientific & Technical Consulting service helps manufacturers design testing strategies that are both scientifically sound and efficiently scoped — avoiding both gaps and unnecessary redundancy.

Ready to build a defensible, submission-ready combination product characterization program? Contact Materials Metric today to speak with our technical team about your specific product, regulatory pathway, and testing requirements. We look forward to supporting your path from development to regulatory approval.

Related Posts from Materials Metric

Explore more insights from our team of materials scientists and analytical experts:

• Non-targeted analysis | Materials Metric | Chem Lab
• Unknown compound identification | Materials Metric
• Extraction conditions | Materials Metric | Chem Lab
• Exhaustive extraction | Materials Metric | Chem Lab

The post Combination product characterization | Materials Metric appeared first on Comprehensive Materials Testing and Analytical Services at Materials Metric.

Extraction conditions govern every step of how a solvent interacts with a material to release chemical compounds. Furthermore, they influence which extractables appear, at what concentrations, and whether the data supports downstream toxicological or biocompatibility assessments. Consequently, getting these parameters right is not optional — it is foundational.

In addition, regulators including the FDA, ISO, and USP expect extraction protocols to reflect worst-case clinical use scenarios. Therefore, laboratories must justify every parameter choice with scientific rationale. This post explains what extraction conditions are, why they matter, and how to select them correctly for compliant, defensible testing.

Key Takeaways

• Extraction conditions — including solvent, temperature, time, and agitation — directly control which chemical compounds a test can detect.
• Regulatory frameworks such as ISO 10993-18 Chemical Characterization and USP require scientifically justified extraction parameters.
• Exaggerated conditions are often used deliberately to reveal the full extractable profile of a material.
• Solvent selection must reflect the intended clinical or end-use environment to produce relevant data.
• Method development and validation are essential before extraction conditions can support regulatory submissions.
• Poorly chosen extraction conditions can cause false negatives — missing hazardous compounds — or false positives that delay product approval.

Extraction conditions: the controlled set of experimental parameters — including solvent type, temperature, duration, surface-area-to-volume ratio, and agitation method — applied during laboratory extraction to systematically release chemical compounds from a material for identification and quantification.

Key fact: Extraction conditions are one of the leading sources of variability in chemical characterization studies — making parameter selection and documentation a critical element of any regulatory submission.

What Are Extraction Conditions and Why Do They Matter?

Extraction conditions define the environment in which a solvent contacts a test material to pull out chemical substances. These parameters collectively determine what gets extracted, how much is recovered, and whether the data is reproducible. For regulatory purposes, every parameter must be justified scientifically.

Moreover, extraction conditions directly affect your ability to detect low-level extractables that could pose patient safety risks. Poorly chosen parameters can cause critical compounds to remain undetected. Consequently, regulators require laboratories to demonstrate that their extraction approach provides a thorough, worst-case profile of a material’s chemical output.

The Core Parameters That Define Extraction Conditions

Several key variables define extraction conditions in any laboratory protocol. These include solvent type, extraction temperature, extraction duration, the surface-area-to-volume (SA/V) ratio, agitation method, and the number of extraction cycles. Each parameter interacts with the others, so changes to one can amplify or diminish the effect of another.

For example, increasing temperature often accelerates solvent penetration and compound release. Similarly, extending duration typically increases total extractable yield. However, excessive temperature or time can also degrade heat-sensitive compounds, producing artifacts that misrepresent the material’s true chemical profile.

How Extraction Conditions Relate to Regulatory Expectations

Regulatory agencies do not prescribe a single universal extraction protocol. Instead, they require that extraction conditions be scientifically justified and appropriate for the material and its intended use. The ISO 10993-18 Chemical Characterization standard explicitly states that extraction conditions should simulate or exaggerate clinical contact conditions.

Furthermore, USP General Chapter <232> Elemental Impurities sets limits on specific elements that laboratories must reliably extract and quantify. In addition, FDA guidance documents for drug-device combination products and container closure systems reference extraction parameters as a key documentation requirement. Therefore, your extraction protocol is as important as the analytical method itself.

Our team at Materials Metric provides Method Development & Validation services specifically designed to help clients build scientifically defensible extraction protocols that satisfy these expectations.

How Do Solvent Selection and Extraction Conditions Interact?

Solvent selection is arguably the single most consequential extraction condition choice a scientist makes. The solvent must be chemically compatible with the test material, capable of dissolving the target compounds, and representative of the clinical or end-use environment. Notably, no single solvent captures every chemical class from every material type.

Therefore, most comprehensive extractables studies use multiple solvents — typically polar, non-polar, and aqueous — to ensure broad chemical coverage. This multi-solvent approach reflects guidance from both ISO 10993-18 and industry best practices for medical devices and pharmaceutical packaging. Our Chemical & Analytical Testing services incorporate this systematic approach to solvent selection.

Polar vs. Non-Polar Solvents: Choosing Based on Material Chemistry

Polar solvents such as water, ethanol, and isopropanol preferentially extract hydrophilic compounds, including ionic species, water-soluble additives, and certain organic acids. By contrast, non-polar solvents such as hexane, dichloromethane, and chloroform are more effective at extracting lipophilic compounds — plasticizers, antioxidants, lubricants, and unreacted monomers.

Importantly, the polarity of the solvent should align with the polarity of the clinical contact fluid. For instance, devices that contact lipid-rich tissues may warrant non-polar solvent extraction to simulate that environment. Meanwhile, devices exposed only to saline or blood plasma may need aqueous and mild polar solvents as primary extraction vehicles.

Simulated Body Fluids as Extraction Conditions

In many biocompatibility studies, laboratories replace or supplement organic solvents with simulated body fluids. These include simulated gastric fluid, simulated intestinal fluid, artificial saliva, and isotonic saline. Specifically, these media mimic the pH, ionic strength, and enzymatic environment a device encounters during patient use.

However, simulated body fluids often extract far fewer compounds than aggressive organic solvents. Furthermore, they may miss non-polar extractables that would dissolve in tissue lipids. As a result, most ISO 10993-18-compliant protocols use simulated body fluids alongside more aggressive solvents to capture both clinically relevant and worst-case chemical profiles. Our Biocompatibility & Toxicity Testing team can advise on appropriate fluid selection for your specific device type.

Solvent Compatibility and Material Integrity

A critical but often overlooked aspect of extraction conditions is solvent compatibility with the test material. Aggressive solvents such as dichloromethane can dissolve or swell certain polymers, causing structural breakdown rather than surface extraction. Consequently, extracted quantities may be artificially elevated, producing data that does not reflect clinical reality.

Therefore, scientists must evaluate whether the chosen solvent degrades the material before committing to a protocol. Visual inspection, mass loss measurement, and mechanical property testing before and after extraction can confirm material integrity. In addition, methods like FTIR Analysis can confirm whether extraction caused structural changes in the polymer matrix.

What Role Do Temperature and Time Play in Extraction Conditions?

Temperature and extraction time are among the most powerful levers available for controlling extraction intensity. Elevating temperature increases molecular kinetic energy, accelerating diffusion of compounds from the material into the solvent. Similarly, extending extraction time allows more complete equilibration between the material and the extracting medium.

However, neither parameter can be increased without limit. Moreover, overly aggressive conditions may produce degradation products, modify labile compounds, or cause solvent evaporation that skews concentration data. Therefore, laboratories must balance extraction efficiency against chemical stability when selecting these conditions.

Temperature Selection: Reflux, Elevated, and Ambient Conditions

Laboratory extraction protocols commonly operate at three temperature levels. Ambient extraction (typically 20–25°C) is used for thermally sensitive materials or when simulating room-temperature storage conditions. Elevated temperature extraction (37–60°C) mimics body temperature or accelerated migration scenarios.

Meanwhile, reflux conditions at or near the solvent’s boiling point are used for exhaustive extraction — the goal being to recover the maximum possible extractable burden. For example, ISO 10993-18 recommends reflux or elevated temperatures when the objective is to characterize the complete chemical inventory of a material. For more detail on this approach, see our related article on exhaustive extraction.

Extraction Duration and Multiple Extraction Cycles

Extraction time strongly influences total yield, particularly for compounds embedded deep within a polymer matrix. Short extractions (1–3 hours) may capture surface-associated compounds but miss bulk matrix constituents. Longer extractions (24–72 hours) or repeated extraction cycles provide more complete recovery.

Furthermore, sequential multi-cycle extraction — where the same material is extracted repeatedly with fresh solvent — can reveal how extractable release diminishes over time. This approach helps distinguish between surface contamination and matrix-embedded compounds. In addition, it supports modeling of cumulative patient exposure over device lifetime, which is a key input into Biocompatibility & Toxicity Testing risk assessments.

Balancing Extraction Conditions to Avoid Artifacts

Artificially harsh extraction conditions — extreme temperature combined with very long duration — can generate thermal degradation products that do not exist under normal use. Consequently, analysts may detect and report compounds that would never actually migrate to a patient. These artifacts create unnecessary regulatory burden and toxicological evaluation work.

Therefore, extraction conditions must strike a deliberate balance: aggressive enough to reveal the full extractable profile, but controlled enough to avoid generating misleading data. Notably, this balance is where expert laboratory judgment and rigorous Method Development & Validation are most critical. Published methodology in ScienceDirect – Analytical Methods provides extensive peer-reviewed guidance on establishing these boundaries.

Quick note: When extraction conditions are too mild, hazardous compounds can remain undetected — creating a false sense of safety. When they are too harsh, laboratories generate degradation artifacts that trigger unnecessary toxicological investigations and delay product approval.

Surface-Area-to-Volume Ratio in Extraction Conditions

The surface-area-to-volume (SA/V) ratio is a critical geometric extraction condition that controls how much material surface contacts a given volume of solvent. A higher SA/V ratio exposes more material surface per milliliter of extractant, typically yielding higher extractable concentrations. Consequently, this parameter strongly affects detection sensitivity and total extracted mass.

Regulatory guidelines such as ISO 10993-12 provide specific SA/V ratios based on material category — for example, 6 cm²/mL for devices with flat or tubular geometries. Furthermore, using a non-standard SA/V ratio without justification can invalidate a study in the eyes of a regulatory reviewer.

How SA/V Ratio Affects Extractables Concentration

A higher SA/V ratio concentrates extractables into a smaller solvent volume, making trace-level compounds easier to detect. For example, cutting a device into small pieces before extraction dramatically increases exposed surface area. However, cutting also alters the material’s surface characteristics — introducing cut-edge artifacts not present in the finished device.

Therefore, analysts must document sample preparation steps in detail. Moreover, they should justify whether cut pieces, intact samples, or powdered material best represents clinical use. Our related article on extractables vs leachables explains how this distinction affects the relevance of extraction data to actual patient exposure.

Agitation Methods and Their Effect on Extraction Efficiency

Agitation during extraction helps renew the solvent-material interface, preventing saturation of the boundary layer and improving mass transfer. Common agitation methods include orbital shaking, magnetic stirring, sonication, and reflux. Specifically, each method imparts a different level of mechanical energy and turbulence.

Sonication, for instance, is particularly effective for breaking up surface films and enhancing compound release from complex geometries. Meanwhile, gentle orbital shaking mimics more physiologically relevant contact scenarios. In addition, reflux continuously cycles solvent across the material surface, providing both thermal and physical agitation simultaneously.

Choosing the right agitation method is therefore part of designing appropriate extraction conditions — not an afterthought. Our Wet Chemistry & Classical Analytical Methods team applies validated agitation protocols tailored to each material type and regulatory context.

Which Analytical Techniques Best Support Extraction Conditions Studies?

Selecting the right analytical technique is just as important as defining the extraction conditions themselves. Furthermore, the analytical method must match the expected chemical classes, concentration ranges, and regulatory detection limits for the material under study. Consequently, most comprehensive studies combine multiple complementary techniques.

Our Chemical & Elemental Characterization services cover the full range of analytical platforms needed to support extractables and leachables studies across industries.

Elemental Analysis: ICP-MS, ICP-OES, and AAS

Inductively coupled plasma mass spectrometry (ICP-MS) is the gold standard for trace elemental analysis in extraction studies. Specifically, it can quantify metals and metalloids at parts-per-trillion levels — essential when meeting the strict limits set by USP Elemental Impurities guidance. Moreover, ICP-MS provides multi-element capability in a single analytical run.

ICP optical emission spectrometry (ICP-OES) offers a complementary approach for higher-concentration elemental analysis. By contrast, atomic absorption spectrometry (AAS) is element-specific and best suited to targeted, single-element quantification. Together, these techniques address the full spectrum of elemental extraction conditions requirements across pharmaceutical and medical device applications.

Organic Extractables: GC-MS and HPLC

Organic extractables require chromatographic separation before identification and quantification. GC-MS Analysis excels at identifying volatile and semi-volatile organic compounds — including plasticizers, antioxidants, oligomers, and residual processing solvents. In addition, it provides library-matchable mass spectra that support confident compound identification.

For non-volatile, thermally labile, or polar organic compounds, HPLC Analysis is the preferred platform. Furthermore, coupling HPLC to high-resolution mass spectrometry enables detection of trace-level unknowns that standard UV detection would miss. These techniques together ensure that extraction conditions studies generate chemically comprehensive extractable profiles.

Spectroscopic Confirmation of Extracted Compounds

Beyond chromatographic identification, spectroscopic techniques provide structural confirmation and surface characterization. FTIR Analysis rapidly identifies functional groups in extracted residues and confirms polymer identity. Similarly, NMR Spectroscopy delivers detailed structural information on isolated extractable compounds, supporting unambiguous identification.

For inorganic surface species, XPS Analysis reveals elemental oxidation states at the material surface — useful for understanding which chemical forms are present before extraction begins. Additionally, Raman Spectroscopy can characterize particulates or residues in the extraction solution without extensive sample preparation. Combining these techniques builds a robust analytical foundation for any extraction conditions study.

How Do Extraction Conditions Vary Across Industries?

Different industries apply extraction conditions within distinct regulatory frameworks, product types, and risk contexts. However, the underlying scientific principles remain consistent. Understanding how these applications differ helps laboratories design protocols that are both technically sound and contextually appropriate.

Pharmaceutical Packaging and Container Closure Systems

In pharmaceutical manufacturing, extraction conditions studies focus on container closure systems — including vials, stoppers, syringes, and plastic bottles. Regulatory expectations come from FDA guidance and USP Elemental Impurities chapters. Specifically, extraction conditions must simulate the drug product’s solvent, pH, and temperature over its shelf life.

For parenteral drug products, even trace-level extractables carry significant safety implications. Therefore, laboratories use aggressive conditions — elevated temperature, extended duration, and multiple solvents — to map the full extractable profile before patient exposure risk assessment begins. Our Chemical Purity & Contaminant Screening services support these high-sensitivity pharmaceutical applications.

Medical Device Chemical Characterization

Medical device extraction studies operate under ISO 10993-18, which requires extraction conditions to reflect the nature, duration, and frequency of patient contact. Devices with permanent implantation require more exhaustive extraction than short-contact accessories. Furthermore, multi-component devices — such as catheters with adhesive coatings — demand separate extraction of each material.

Consequently, medical device teams must define extraction conditions for each distinct material in a device’s construction. Our article on medical device extractables and leachables provides detailed guidance on navigating this complexity. For specialized support, our Scientific & Technical Consulting team works directly with device manufacturers to design appropriate protocols.

Aerospace, Industrial, and Environmental Applications

Beyond healthcare, extraction conditions studies apply to aerospace materials, food contact materials, and environmental contamination assessments. In aerospace, extraction testing characterizes outgassing and chemical release from composites, sealants, and coatings used in enclosed environments. Moreover, food contact materials require extraction under conditions that simulate food processing temperatures and contact durations.

Environmental monitoring uses extraction conditions to assess contaminant release from soils, sediments, and industrial waste streams. Notably, standardized methods such as toxicity characteristic leaching procedure (TCLP) define specific extraction conditions for regulatory compliance in waste classification. These applications demonstrate that the principles governing extraction conditions extend well beyond pharmaceutical and medical device contexts.

Quality Assurance and Best Practices for Extraction Conditions

Rigorous quality assurance transforms a well-designed extraction protocol into a reproducible, defensible study. Furthermore, it ensures that data submitted to regulators accurately reflects the material under study — not measurement artifacts or laboratory errors. Therefore, quality controls must be embedded throughout every extraction conditions study.

Essential Quality Controls for Extraction Studies

Every extraction study should include procedural blanks, method spikes, and reference standards. Procedural blanks — solvent run through the complete extraction process without sample — identify any background contamination introduced by the laboratory or equipment. Method spikes confirm that the analytical system recovers target compounds at acceptable efficiency.

In addition, replicate extractions from the same material lot confirm that the extraction conditions produce consistent results. Acceptable relative standard deviations (RSDs) for replicate extractions typically fall below 15–20% for organic analytes and 10% for elemental analytes. Documenting these controls fully supports data integrity under regulatory scrutiny. Our Chemical & Analytical Testing laboratory applies comprehensive quality controls to every extraction study.

Documentation and Traceability Requirements

Regulators expect complete documentation of every extraction conditions parameter — not just the results. Specifically, the extraction protocol must record solvent lot numbers, instrument calibration records, sample preparation timestamps, and analyst identity. Consequently, any deviation from the planned protocol must be captured and justified in the study record.

Electronic laboratory notebooks (ELNs) and laboratory information management systems (LIMS) support traceability and audit readiness. Furthermore, version-controlled standard operating procedures (SOPs) ensure that extraction conditions remain consistent across analysts and studies over time. Our Method Development & Validation services include full SOP development and documentation support.

Comparing Common Extraction Conditions: A Summary Table

The following table summarizes common extraction condition choices, their typical applications, and their key tradeoffs. Use this comparison as a starting framework — your specific material and regulatory context will ultimately guide final parameter selection.

For guidance on how extraction data connects to the broader regulatory picture, see our related article on chemical characterization vs biocompatibility. Additionally, published methodology from ScienceDirect offers peer-reviewed benchmarks for extraction conditions across material types.

Frequently Asked Questions About Extraction Conditions

What are extraction conditions in chemical characterization?

Extraction conditions are the controlled experimental parameters — including solvent type, temperature, duration, SA/V ratio, and agitation — used to release chemical compounds from a material. Specifically, they determine which substances are detected, at what concentrations, and whether the data reflects clinical use or worst-case scenarios. Regulatory agencies require these parameters to be scientifically justified and fully documented.

Why do extraction conditions matter for regulatory submissions?

Regulators such as the FDA and ISO expect extraction conditions to reflect the intended use environment of the product. Poorly justified conditions can result in study rejection, requests for additional data, or product approval delays. Furthermore, conditions that are too mild risk missing hazardous compounds — creating a patient safety gap that regulators will not accept.

How do I choose the right solvent for extraction conditions?

Solvent selection depends on the material’s chemistry, the target compound classes, and the clinical contact environment. Generally, laboratories use a combination of polar, non-polar, and aqueous solvents to ensure broad chemical coverage. Moreover, the chosen solvent must not degrade the material in ways that produce extraction artifacts. Our Method Development & Validation team can guide solvent selection for your specific material and regulatory context.

What is the difference between exhaustive and simulated-use extraction conditions?

Exhaustive extraction uses the most aggressive conditions possible — high temperature, long duration, and potent solvents — to recover the maximum total chemical burden from a material. Simulated-use extraction, by contrast, mirrors the actual clinical contact conditions in terms of solvent, temperature, and time. Both serve different regulatory purposes: exhaustive extraction defines the chemical inventory, while simulated-use extraction assesses patient exposure risk.

Can extraction conditions affect biocompatibility assessment outcomes?

Absolutely. The compounds identified and quantified under specific extraction conditions feed directly into toxicological risk assessments and Biocompatibility & Toxicity Testing evaluations. Consequently, if extraction conditions miss key compounds, the toxicological assessment will underestimate patient risk. Conversely, artificially harsh conditions can generate degradation products that trigger unnecessary in vivo testing.

How often should extraction conditions be revalidated?

Extraction conditions require revalidation whenever there is a significant change to the material formulation, manufacturing process, supplier, or intended use. Additionally, regulatory agencies may request revalidation if new analytical methods become available that offer improved sensitivity or specificity. Periodic review — typically every two to three years — also represents good laboratory practice. Our Scientific & Technical Consulting team can assess whether your current extraction protocol remains fit for purpose.

Conclusion

Extraction conditions are the foundation of every credible chemical characterization study. Selecting the right solvent, temperature, duration, SA/V ratio, and agitation method requires both scientific expertise and regulatory awareness. Furthermore, every parameter choice must be documented, justified, and validated before supporting a regulatory submission.

Getting extraction conditions right protects patients, accelerates product approval, and builds long-term confidence in your quality system. By contrast, poorly designed extraction protocols introduce risk at every stage — from missed hazardous compounds to unnecessary toxicological investigations. Consequently, this is not an area where guesswork or generic defaults are acceptable.

Moreover, as materials grow more complex and regulatory expectations continue to evolve, the need for expert-designed extraction protocols will only increase. Whether you are developing a new medical device, qualifying pharmaceutical packaging, or characterizing an industrial material, the extraction conditions you choose will define the quality and defensibility of your data.

At Materials Metric, our team of analytical chemists, toxicologists, and regulatory specialists brings deep expertise to every extraction conditions study. Therefore, if you are ready to design, validate, or improve your extraction protocol, we invite you to contact Materials Metric today. We will work with you to build an extraction approach that meets your scientific goals, satisfies regulatory expectations, and delivers reliable, reproducible results.

Related Posts from Materials Metric

Explore more insights from our team of materials scientists and analytical experts:

• Exhaustive extraction | Materials Metric | Chem Lab
• Medical device extractables and leachables | Materials Metric
• Extractables vs leachables | Materials Metric | Chem Lab
• 510k testing requirements | Materials Metric | Compliance

The post Extraction conditions | Materials Metric | Chem Lab appeared first on Comprehensive Materials Testing and Analytical Services at Materials Metric.

Furthermore, Exhaustive extraction is a sample preparation technique that removes virtually all target analytes from a solid, liquid, or semi-solid material by repeatedly exposing it to a solvent or extraction medium until no further analyte is recovered. Moreover, for engineers, chemists, and regulatory professionals, this approach provides the most complete chemical profile of a material — making it essential for safety testing, regulatory compliance, and quality control. At Materials Metric, exhaustive extraction forms the backbone of many advanced characterization workflows.

In addition, understanding when and how to apply exhaustive extraction can determine whether a product passes or fails regulatory scrutiny. Furthermore, the technique directly informs risk assessments for medical devices, pharmaceutical packaging, industrial components, and consumer goods. Incomplete extraction leaves residual analytes undetected — consequently exposing manufacturers to liability, product recalls, and patient harm.

Moreover, global standards such as ISO 10993-18 Chemical Characterization and USP General Chapter <232> Elemental Impurities explicitly reference exhaustive extraction protocols as the basis for conservative worst-case chemical characterization. Therefore, laboratories that master this methodology deliver data that regulators, auditors, and safety assessors can trust without reservation.

Key Takeaways

• Exhaustive extraction maximizes analyte recovery from a material, ensuring the most complete chemical profile.
• Regulatory frameworks including ISO 10993-18 and USP <232> require exhaustive or exaggerated extraction for worst-case safety assessments.
• Common methods include Soxhlet extraction, pressurized solvent extraction, microwave-assisted extraction, and reflux extraction.
• Proper solvent selection, temperature control, and extraction duration are critical variables that determine data reliability.
• Exhaustive extraction works alongside analytical techniques such as GC-MS Analysis, HPLC Analysis, and NMR Spectroscopy to identify and quantify extractable compounds.
• Method development and validation are essential steps before exhaustive extraction data can support regulatory submissions.

Exhaustive Extraction: A sample preparation strategy that applies repeated or continuous solvent contact to a material until analyte recovery reaches a plateau, ensuring that virtually all extractable chemical species are captured and quantified for safety and characterization purposes.

Key Fact: Exhaustive extraction is widely recognized as one of the most critical steps in chemical characterization workflows for medical devices and pharmaceutical packaging — because incomplete extraction routinely understates a material’s true chemical burden, potentially masking compounds that exceed regulatory safety thresholds.

What Is Exhaustive Extraction and How Does It Work?

Exhaustive extraction systematically drives analytes out of a material matrix by saturating it with solvent, then refreshing or recirculating that solvent until the analyte concentration in each subsequent fraction drops to a negligible level. However, in practice, laboratories track recovery across multiple extraction cycles. Consequently, they stop the process only when successive fractions show no meaningful additional yield — a point often called “extraction to exhaustion.”

This approach contrasts sharply with simpler single-pass or time-limited extraction methods. Those shorter protocols may capture only a fraction of the total extractable load. Therefore, exhaustive extraction becomes necessary whenever regulations demand a worst-case or conservative chemical profile.

Core Principles Behind Exhaustive Extraction

At its core, exhaustive extraction relies on thermodynamic partitioning. Analytes migrate from the solid or semi-solid matrix into the solvent phase based on their solubility, polarity, and molecular affinity for the chosen medium. Increasing temperature, agitation, or surface area accelerates this migration. However, the process only reaches a true endpoint when the partition equilibrium has been fully exploited across enough cycles or a long enough extraction window.

Importantly, exhaustive extraction is not a single method — it is a performance goal. Various techniques can achieve it, including continuous Soxhlet extraction, pressurized liquid extraction, and extended reflux procedures. The selection depends on the matrix type, analyte volatility, and the downstream analytical instrument receiving the extract.

Exhaustive Extraction vs. Partial or Simulated-Use Extraction

Regulatory guidance distinguishes clearly between extraction types. Simulated-use extraction mimics realistic patient or consumer contact conditions — for example, soaking a catheter in saline at body temperature for 24 hours. By contrast, exhaustive extraction applies far more aggressive conditions to capture every possible leachable, regardless of how the product is actually used.

Similarly, partial or time-limited extractions serve screening purposes. They work well for routine quality checks. However, they cannot replace exhaustive extraction when regulators demand a full chemical inventory of a material’s extractable burden. Specifically, ISO 10993-18 Chemical Characterization classifies exhaustive extraction as the appropriate technique when conducting chemical characterization studies intended to support biological safety evaluations.

Why Exhaustive Extraction Is Essential for Regulatory Compliance

Regulatory agencies worldwide — including the FDA, EMA, and ISO technical committees — increasingly demand comprehensive chemical data before approving medical devices, drug packaging, and food-contact materials. Exhaustive extraction provides the chemical inventory these agencies require. Furthermore, it demonstrates that a manufacturer has made every reasonable effort to identify harmful compounds before placing a product on the market.

In addition, the extractables profile generated by exhaustive extraction feeds directly into toxicological risk assessments. Toxicologists use the resulting data to calculate the analytical evaluation threshold (AET), apply safety margins, and determine whether any compound exceeds a threshold of toxicological concern (TTC). Without exhaustive extraction data, these calculations lack the foundational completeness regulators expect.

ISO 10993-18 and Exhaustive Extraction Requirements

ISO 10993-18 defines the chemical characterization framework for medical devices. Specifically, it requires laboratories to select extraction conditions — including solvents, temperature, and duration — that maximize analyte yield from the device material. Exhaustive extraction satisfies this requirement by design.

Moreover, the standard asks laboratories to demonstrate that extraction is complete. Therefore, teams must show that the final extraction fraction contains analyte concentrations at or near the detection limit. This fraction-by-fraction verification distinguishes a rigorous exhaustive extraction study from a simple soak-and-test approach. Our Method Development & Validation service builds this documentation systematically into every study protocol.

USP <232> and Elemental Impurities: The Role of Exhaustive Extraction

For pharmaceutical manufacturers, USP General Chapter <232> Elemental Impurities sets legally enforceable limits on elemental contaminants in drug products. Exhaustive extraction of container-closure systems and drug-contact polymers forms the basis for demonstrating that elemental contributions from packaging stay within permissible daily exposure (PDE) limits.

Notably, the standard specifies that extraction conditions must be “worst-case” — meaning they should release the maximum possible elemental burden from the material. Exhaustive extraction fulfills this criterion more reliably than any other approach. Our Chemical Purity & Contaminant Screening service applies these protocols to support USP <232> submissions with complete, defensible datasets.

FDA Expectations for Extractables Studies

The FDA’s guidance for combination products, drug-device combinations, and container-closure systems all reference extractables and leachables (E&L) studies. For the extractables phase, exhaustive extraction defines the upper bound of what a material can possibly release. Consequently, regulators treat exhaustive extraction data as the most conservative and protective dataset available.

Additionally, the FDA expects laboratories to justify their extraction conditions with scientific rationale. Poorly documented or incomplete extraction studies frequently trigger data deficiency letters during the review process. By contrast, well-validated exhaustive extraction studies accelerate approval timelines by preemptively addressing agency concerns. Our Chemical & Analytical Testing team designs every study with this regulatory defensibility in mind.

Common Exhaustive Extraction Methods and Their Applications

Several proven techniques achieve exhaustive extraction across different material types and analyte classes. Choosing the right method depends on the material matrix, the target analytes’ chemical properties, and the downstream analytical platform. In addition, method selection must account for solvent compatibility, thermal stability of the material, and any regulatory preferences for specific extraction approaches.

Below is a comparison table summarizing the most widely used exhaustive extraction techniques, their operating principles, and their primary applications.

Soxhlet Extraction: The Classic Exhaustive Method

Soxhlet extraction has served as the reference standard for exhaustive extraction for over a century. The technique continuously cycles fresh solvent through a sample thimble, ensuring that the concentration gradient driving analyte migration is always maximized. Furthermore, the condensed solvent repeatedly contacts the material — sometimes for 12 to 48 hours — making it one of the most thorough approaches available.

Regulators and pharmacopoeias reference Soxhlet extraction frequently because its performance is well-characterized and reproducible. However, it requires relatively large solvent volumes and long extraction times. Therefore, many modern laboratories complement Soxhlet extraction with faster alternatives for routine work, reserving it for method validation or worst-case regulatory studies.

Pressurized Liquid Extraction and Microwave-Assisted Approaches

Pressurized liquid extraction (PLE), also called accelerated solvent extraction (ASE), applies heat and pressure simultaneously. As a result, solvent viscosity drops and analyte diffusivity increases — dramatically cutting extraction time without sacrificing recovery. Moreover, PLE’s automated fraction collection simplifies the process of verifying extraction completeness by comparing analyte content across successive fractions.

Microwave-assisted extraction offers similar speed advantages. Specifically, microwave energy heats polar solvents rapidly and uniformly, disrupting the matrix and releasing analytes efficiently. Meanwhile, both methods require careful temperature optimization to avoid degrading thermolabile target compounds. Our Wet Chemistry & Classical Analytical Methods team selects and validates the appropriate technique for each unique material and analyte combination.

Selecting the Right Solvent for Exhaustive Extraction

Solvent selection profoundly influences exhaustive extraction outcomes. A solvent must match the polarity of the target analytes and penetrate the material matrix effectively. In addition, it must be compatible with the downstream analytical method — for example, GC-MS requires volatile solvents that evaporate cleanly, while HPLC tolerates a broader range of aqueous and organic media.

Regulatory guidance recommends using multiple solvents with different polarity profiles — typically a non-polar solvent like hexane, a mid-polarity solvent like isopropanol, and a polar solvent like water — to capture the full spectrum of extractable compounds. Consequently, a single-solvent exhaustive extraction may miss entire classes of chemicals. Our Chemical & Elemental Characterization experts design multi-solvent extraction strategies that maximize chemical coverage across diverse material types.

Quick Note: When selecting solvents for exhaustive extraction, always consider the material’s thermal stability, the analyte’s vapor pressure, and the sensitivity of your downstream detector. A mismatch between any of these factors can result in incomplete recovery or instrument contamination — both of which compromise data integrity and regulatory defensibility.

Analytical Techniques That Work With Exhaustive Extraction

Exhaustive extraction generates a concentrated chemical profile — but the value of that profile depends entirely on the analytical method used to interrogate it. Therefore, laboratories pair exhaustive extraction with powerful instrumental techniques that can detect, identify, and quantify analytes at trace and ultra-trace levels. Selecting the right instrument for the extract type is as critical as the extraction itself.

Furthermore, different analytical platforms excel at different compound classes. Organic extractables require separation-based methods. Elemental impurities demand atomic spectroscopy. In addition, structural confirmation often requires spectroscopic techniques that provide molecular fingerprints rather than simple concentration data.

ICP-MS and ICP-OES for Elemental Analysis

Inductively coupled plasma mass spectrometry (ICP-MS) and ICP-OES are the dominant techniques for measuring elemental impurities in exhaustive extraction studies. ICP-MS offers exceptional sensitivity — detecting elements at parts-per-trillion levels. Consequently, it satisfies the stringent detection requirements set by USP Elemental Impurities guidelines for pharmaceutical applications.

ICP-OES provides excellent precision across a wide dynamic range and handles complex matrices reliably. Moreover, both techniques analyze multiple elements simultaneously, making them highly efficient for screening extracts from polymer components, elastomers, and metal alloys. Our Chemical & Elemental Characterization service routinely applies these platforms to exhaustive extraction studies requiring defensible elemental data.

GC-MS and HPLC for Organic Extractables

Organic extractables — including plasticizers, antioxidants, residual monomers, and processing aids — require chromatographic separation before detection. GC-MS Analysis excels at volatile and semi-volatile organics, delivering both retention-time identification and mass spectral confirmation. Specifically, it remains the gold standard for identifying unknown compounds in exhaustive extraction studies targeting polymer additives.

For non-volatile or thermally labile compounds, HPLC Analysis provides a complementary separation mechanism. By contrast, GC requires compounds to vaporize without degrading — a requirement that many pharmaceutical excipients and oligomers cannot meet. Therefore, a comprehensive exhaustive extraction program typically employs both GC-MS and HPLC together to achieve full organic coverage.

Complementary Spectroscopic Confirmation Techniques

When chromatographic data alone cannot confirm a compound’s identity, spectroscopic techniques step in. FTIR Analysis rapidly identifies functional groups in concentrated extracts. Furthermore, NMR Spectroscopy provides definitive structural elucidation for unknown extractables, even at low concentrations when combined with solvent suppression techniques.

Additionally, Raman Spectroscopy complements FTIR by characterizing inorganic fillers, pigments, and surface coatings that may contribute to an extract’s chemical load. Together, these spectroscopic tools transform a raw exhaustive extraction dataset into a fully annotated chemical inventory — which regulators and toxicologists require for complete safety evaluations.

Industry-Specific Applications of Exhaustive Extraction

Exhaustive extraction applies across a remarkably broad range of regulated industries. Each sector brings unique material types, contact conditions, and regulatory frameworks. However, the underlying goal remains consistent: generate the most complete chemical dataset possible before a product reaches end users.

The table below summarizes how exhaustive extraction applies across four major industries, highlighting the key drivers and primary analytical methods used in each context.

Medical Devices and Biocompatibility Testing

Medical device manufacturers depend on exhaustive extraction to generate the chemical inventory required for biological safety evaluations. Specifically, the extractables data feeds into ISO 10993-1 risk assessments, where toxicologists evaluate every identified compound against established safety thresholds. Our Biocompatibility & Toxicity Testing service integrates exhaustive extraction data directly into these evaluations.

Moreover, the stakes are exceptionally high in this sector. Devices that contact blood, tissue, or implantation sites face the most rigorous scrutiny. Consequently, laboratories conducting exhaustive extraction for medical devices must demonstrate not only recovery completeness but also analytical coverage across both organic and inorganic compound classes.

Pharmaceutical Packaging and Container-Closure Systems

Pharmaceutical manufacturers face a dual challenge: ensuring the drug product remains stable and ensuring that packaging materials do not contribute harmful extractables. Exhaustive extraction of stoppers, vial closures, syringe barrels, and film laminates reveals every compound capable of migrating into a drug formulation.

In addition, the analytical data supports threshold calculations for the analytical evaluation threshold (AET). Laboratories must detect compounds at concentrations well below the AET — which, for many drug products, falls in the low parts-per-billion range. Therefore, exhaustive extraction must pair with highly sensitive detection platforms such as ICP-MS and high-resolution LC-MS. Published research available through ScienceDirect continues to advance method development in this technically demanding field.

Aerospace, Environmental, and Consumer Product Applications

Aerospace manufacturers use exhaustive extraction to qualify sealants, composite matrices, and lubricant residues on flight-critical components. Notably, trace organic contamination on aerospace surfaces can cause adhesion failures or sensor degradation — making chemical completeness a safety issue, not just a compliance issue.

For environmental and food-contact applications, exhaustive extraction quantifies migrants from plastic packaging before products enter regulated markets. Furthermore, consumer product safety programs use exhaustive extraction data to verify compliance with regulations restricting heavy metals, phthalates, and other hazardous substance classes. Our Chemical & Analytical Testing team supports clients across all these sectors with fit-for-purpose extraction and analysis programs.

Quality Assurance and Best Practices in Exhaustive Extraction Studies

Exhaustive extraction data only has regulatory value if the laboratory can demonstrate that it was generated under controlled, validated, and documented conditions. Therefore, quality assurance practices are not optional additions — they are foundational requirements that every credible extraction study must satisfy.

Specifically, laboratories must control variables including solvent purity, extraction vessel cleanliness, temperature uniformity, and sample preparation protocols. Each uncontrolled variable introduces a potential source of bias that could either overstate or understate the true extractable burden of a material.

Method Development and Validation for Exhaustive Extraction

No two materials are chemically identical — consequently, no single exhaustive extraction method suits every project. Effective method development starts with a material characterization review that considers the polymer type, processing history, and intended use environment. Our Method Development & Validation team constructs extraction protocols that address these variables systematically.

Validation then confirms that the method achieves acceptable accuracy, precision, linearity, and recovery across the analyte range of interest. Furthermore, spike recovery experiments verify that the extraction process releases spiked analytes quantitatively — a direct measure of method exhaustiveness. Without this validation evidence, regulatory agencies have no basis for trusting the completeness of the resulting chemical profile.

Demonstrating Extraction Completeness: Fraction-by-Fraction Monitoring

Proving extraction completeness is one of the defining challenges in exhaustive extraction studies. The most rigorous approach collects multiple sequential fractions and analyzes each separately. Importantly, the process continues until the analyte concentration in each new fraction drops to at or below the method’s limit of quantification.

This fraction-by-fraction strategy generates a depletion curve — a visual and quantitative record showing that analyte recovery is genuinely exhausted. Regulators and auditors respond well to this evidence because it directly demonstrates the laboratory’s commitment to conservative, worst-case characterization. By contrast, studies that terminate extraction based on time alone, rather than demonstrated analyte depletion, face increased scrutiny during regulatory review.

Avoiding Common Pitfalls in Exhaustive Extraction Studies

Several recurring errors undermine otherwise well-designed exhaustive extraction programs. Below are the most critical pitfalls and how to avoid them:

• Insufficient solvent polarity range: Using a single solvent misses entire compound classes. Always apply at least two solvents covering polar and non-polar analytes.
• Premature extraction termination: Stopping before analyte depletion is confirmed leaves residual extractables undetected and the data incomplete.
• Contaminated labware: Trace-level analytes require scrupulously clean glassware and reagent-grade or better solvents to avoid false positives.
• Poor sample surface area preparation: Cutting or grinding materials to increase surface area accelerates extraction significantly; failure to standardize this step introduces variability.
• Inadequate analytical sensitivity: If the detection limit exceeds the analytical evaluation threshold, the method cannot confirm safety — rendering the entire study non-compliant.
• Missing method validation documentation: Regulatory submissions without validation data risk outright rejection, regardless of extraction quality.

Our Scientific & Technical Consulting team regularly assists organizations in identifying and correcting these issues before they reach regulatory review — saving significant time and cost in the submission process.

Frequently Asked Questions About Exhaustive Extraction

What is the difference between exhaustive extraction and simulated-use extraction?

Exhaustive extraction applies aggressive solvent conditions — high temperature, long duration, and multiple solvents — to recover virtually all chemical species a material can release. Simulated-use extraction, by contrast, mimics realistic contact conditions such as body temperature, physiological fluids, and expected contact duration. Regulators use exhaustive extraction to establish the absolute worst-case chemical inventory and simulated-use extraction to estimate real-world patient exposure. Both study types often appear together in a complete extractables and leachables (E&L) program.

How do laboratories verify that an exhaustive extraction is truly complete?

Laboratories verify completeness by collecting sequential extraction fractions and measuring analyte concentration in each one. The extraction process reaches a genuine endpoint when successive fractions show analyte concentrations at or near the method’s limit of quantification. Furthermore, some protocols require that the final fraction contains less than a specified percentage — often 1–5% — of the total analyte recovered across all fractions combined. This fraction-by-fraction monitoring provides documented, defensible evidence of extraction exhaustiveness.

Which solvents are most commonly used in exhaustive extraction for medical devices?

ISO 10993-18 recommends using solvents that bracket the polarity range of likely extractables. In practice, laboratories typically apply isopropanol or ethanol as mid-polarity solvents, hexane or heptane for non-polar extractables, and water or acidified water for polar and ionic species. Moreover, some protocols add dimethyl sulfoxide (DMSO) for materials with particularly high chemical complexity. Using multiple solvents ensures that both hydrophilic and lipophilic compounds receive adequate coverage in the final chemical inventory.

Is exhaustive extraction required for all medical device submissions?

Not every device requires exhaustive extraction — regulatory requirements scale with patient risk. Devices with brief, external contact may satisfy regulators with simulated-use extraction alone. However, implantable devices, long-term contact devices, and those contacting blood or cerebrospinal fluid almost always require exhaustive extraction to support a complete biological safety evaluation under ISO 10993-18. Therefore, manufacturers should consult their regulatory strategy early to determine which extraction approach their specific device classification demands.

Can exhaustive extraction detect both organic and inorganic extractables?

Yes — but achieving comprehensive coverage requires using separate analytical platforms for each compound class. Organic extractables are best captured using GC-MS and HPLC, while inorganic elemental impurities require ICP-MS or ICP-OES. Consequently, a complete exhaustive extraction study routes extract fractions to multiple instruments. Additionally, techniques such as FTIR and NMR provide structural confirmation for unknowns that chromatographic retention time alone cannot definitively identify. This multi-technique approach is standard practice for regulatory-grade exhaustive extraction programs.

How long does an exhaustive extraction study typically take?

Study timelines vary considerably based on material complexity, the number of solvents used, extraction technique, and analytical method selection. A straightforward Soxhlet extraction may run 24–48 hours continuously, while a full multi-solvent exhaustive extraction program with subsequent analytical testing, data processing, and report generation often requires two to six weeks end-to-end. Furthermore, method development and validation — required before a study can support regulatory submissions — can add several additional weeks. Early engagement with your testing laboratory and clear scope definition significantly reduce overall project timelines.

Conclusion

Exhaustive extraction remains one of the most powerful and regulatory-critical tools available to materials scientists, product safety teams, and quality engineers. By systematically driving every recoverable chemical species out of a material matrix, it delivers the comprehensive chemical inventory that modern regulatory frameworks demand. Furthermore, it establishes the scientific foundation for toxicological risk assessment, safety thresholds, and ultimately, product approval.

Mastering exhaustive extraction requires far more than simply soaking a sample in solvent. Consequently, it demands expert method development, rigorous validation, careful solvent selection, and sophisticated multi-technique analytical follow-through. Each variable — from extraction temperature to fraction collection intervals — influences the completeness and regulatory defensibility of the resulting dataset.

At Materials Metric, our integrated approach combines extraction expertise with a full suite of analytical capabilities — including GC-MS Analysis, HPLC Analysis, Chemical & Elemental Characterization, and Biocompatibility & Toxicity Testing — to deliver complete, submission-ready extractables datasets. Moreover, our method development scientists design every exhaustive extraction protocol specifically for your material, your regulatory pathway, and your timeline.

Whether you are developing a new medical device, qualifying pharmaceutical packaging, or assessing an industrial material for chemical compliance, exhaustive extraction is too important to leave to chance. Specifically, incomplete or poorly documented extraction studies cost manufacturers time, money, and market access — outcomes that expert support can reliably prevent.

Ready to discuss your extraction and characterization needs? Contact Materials Metric today to speak with our analytical and regulatory specialists. Our team will help you design a fit-for-purpose exhaustive extraction program that meets your specific regulatory requirements and delivers results you can defend with confidence.

Related Posts from Materials Metric

Explore more insights from our team of materials scientists and analytical experts:

• Medical device extractables and leachables | Materials Metric
• Extractables vs leachables | Materials Metric | Chem Lab
• 510k testing requirements | Materials Metric | Compliance
• Supplier change risk assessment | Materials Metric

The post Exhaustive extraction | Materials Metric | Chem Lab appeared first on Comprehensive Materials Testing and Analytical Services at Materials Metric.

Medical device extractables and leachables are chemical compounds that migrate from device materials into a patient’s body or surrounding environment, posing potential safety risks. Understanding and controlling these substances is a core regulatory requirement for any device that contacts patients directly. At Materials Metric, we help device manufacturers meet these requirements with rigorous, science-driven testing.

Regulatory agencies worldwide — including the FDA, EMA, and ISO — require manufacturers to characterize and assess these chemical migrants. Consequently, E&L studies have become a non-negotiable step in medical device development. Furthermore, failures in this area frequently trigger FDA deficiency letters and submission delays.

Moreover, the complexity of modern devices — combining polymers, adhesives, coatings, and metals — makes thorough chemical characterization more challenging than ever. In addition, evolving standards such as ISO 10993-18 Chemical Characterization continue to raise the analytical bar. Therefore, teams need an experienced laboratory partner to navigate this landscape effectively.

Key Takeaways

• Extractables are chemicals released under aggressive lab conditions; leachables are those actually migrating during clinical use.
• ISO 10993-18 and FDA guidance define the framework for E&L studies in medical devices.
• A tiered testing strategy — screening, identification, quantification — keeps costs and timelines manageable.
• Analytical methods such as GC-MS Analysis, HPLC Analysis, and ICP techniques are central to E&L workflows.
• Toxicological risk assessment determines whether identified leachables are clinically acceptable.
• Early-stage planning of E&L studies saves significant time and cost during regulatory review.

Medical device extractables and leachables: Chemical substances that migrate out of device materials — either under exaggerated laboratory extraction conditions (extractables) or during actual patient use (leachables) — and that must be identified, quantified, and toxicologically assessed to confirm patient safety.

Key fact: Chemical leachables from medical device materials are among the leading causes of biocompatibility failures identified during FDA premarket submissions, making E&L testing one of the highest-impact investments a device manufacturer can make.

What Is the Difference Between Extractables and Leachables?

Many engineers use the terms interchangeably, but extractables and leachables represent distinct concepts with different regulatory implications. Understanding this distinction is the first step in designing a compliant testing strategy. For instance, the analytical methods, solvents, and acceptance criteria differ significantly between the two.

Defining Extractables

Extractables are chemical compounds released from a device material when exposed to exaggerated or aggressive laboratory conditions. Specifically, these conditions use solvents, elevated temperatures, or extended contact times not typical of actual clinical use. The purpose is to identify the full universe of chemicals that could migrate — providing a worst-case picture. Consequently, extractables data serve as a screening tool rather than a direct patient safety assessment.

Common extraction solvents include water, ethanol, isopropanol, and hexane. Furthermore, laboratories often use acidic and basic solutions to capture a broader chemical range. By comparison, the conditions used for leachables studies mimic real clinical exposure far more closely.

Defining Leachables

Leachables, by contrast, are compounds that actually migrate into a drug product, biological fluid, or patient tissue during intended use. Therefore, leachables data reflect real clinical risk far more directly than extractables data. In addition, leachables studies typically use clinically relevant solvents and temperatures that match the device’s use environment.

A key principle is that leachables are generally a subset of extractables. However, some leachables can appear that were not identified in the extractables screen — for example, degradation products formed by chemical reactions during long-term storage. Notably, this is why comprehensive analytical coverage at both stages matters so much.

How Extractables Inform Leachables Testing

Regulatory guidance — especially ISO 10993-18 Chemical Characterization — establishes a direct link between extractables and leachables studies. Specifically, the extractables profile sets the analytical scope for leachables testing. Compounds identified during extraction become the target analytes in leachables studies.

This tiered approach is efficient and scientifically defensible. Furthermore, it allows teams to focus expensive and time-consuming leachables work on the chemicals that genuinely matter. As a result, manufacturers save time and resources without compromising on safety. Our Chemical & Analytical Testing team helps clients design both stages cohesively from the outset.

Why Do Regulatory Agencies Require Medical Device Extractables and Leachables Testing?

Regulatory requirements for medical device extractables and leachables exist because device materials contain complex chemistry. Polymers, adhesives, lubricants, colorants, and processing aids all introduce potential migrants. Moreover, patient exposure can be prolonged, systemic, and — in implantable devices — lifelong.

The ISO 10993 Framework

The ISO 10993 series provides the primary international framework for medical device biocompatibility. Specifically, ISO 10993-18 Chemical Characterization governs chemical characterization of device materials, including E&L testing. It requires manufacturers to identify and quantify chemical constituents and then assess their toxicological risk.

ISO 10993-17 then provides the toxicological risk assessment methodology for identified leachables. Together, these standards form a cohesive chemical safety framework. In addition, ISO 10993-1:2018 introduced a risk-based approach that makes chemical characterization central to biocompatibility evaluation planning.

FDA Guidance on Extractables and Leachables

The FDA’s guidance on biocompatibility aligns closely with ISO 10993 but includes additional expectations specific to the US market. For example, the FDA expects device submissions to include a thorough chemical characterization report as part of the biocompatibility section. Furthermore, FDA reviewers frequently cite inadequate E&L data as a major reason for issuing Additional Information requests.

Our article on FDA biocompatibility deficiencies explores the most common submission gaps in detail. Notably, missing or incomplete extractables data consistently ranks among the top deficiencies. Therefore, early and thorough E&L testing pays dividends at the submission stage.

Device Contact Nature and Duration

The rigor of required E&L testing scales with the device’s contact nature and duration. ISO 10993-1 classifies devices by contact type — surface contact, externally communicating, and implant — and by contact duration: limited (under 24 hours), prolonged (up to 30 days), and permanent (over 30 days).

Consequently, an implantable device requires far more extensive E&L characterization than a skin-contact bandage. Furthermore, blood-contacting and tissue-implanted devices demand the most rigorous analytical and toxicological assessment. By comparison, short-contact surface devices may qualify for a more streamlined approach. For guidance on classification and scope, our Scientific & Technical Consulting team helps manufacturers make defensible decisions early.

How Are Medical Device Extractables and Leachables Studies Designed?

A well-designed E&L study starts with a materials inventory and a clear understanding of device-patient contact. Without this foundation, even the best analytical methods can miss critical migrants. Furthermore, poor study design creates regulatory risk by leaving chemical hazards unidentified.

Step 1 — Building a Material Inventory

The first task is identifying every material component that contacts the patient, drug product, or biological fluid. This inventory includes raw polymers, additives, colorants, adhesives, lubricants, and surface coatings. In addition, manufacturers must consider indirect contact materials — for example, packaging components that may leach into a drug-delivery device.

Each material component requires a supplier-provided formulation disclosure or safety data sheet. However, formulation disclosures are often incomplete due to trade-secret protections. Therefore, laboratory extraction and analysis remain essential even when documentary evidence exists. Our Chemical Purity & Contaminant Screening service helps identify unknowns systematically and efficiently.

Step 2 — Selecting Extraction Conditions

Extraction conditions must reflect both the chemical nature of the materials and the intended use environment. Specifically, ISO 10993-18 recommends a polarity-bracketing solvent approach. This uses at least two solvents — one polar and one nonpolar — to capture the full range of extractable compounds.

Common solvent choices include water and hexane as polarity extremes, with ethanol or isopropanol as intermediate options. Furthermore, acidic and basic solutions help reveal ionic and hydrolytically labile compounds. Temperature and contact duration are also critical variables — elevated temperatures accelerate extraction and capture compounds that appear only under thermal stress. Our team uses Wet Chemistry & Classical Analytical Methods alongside modern instrumentation to ensure complete coverage.

Step 3 — Analytical Method Selection and Validation

Selecting the right analytical methods is arguably the most critical technical decision in an E&L study. No single technique covers all compound classes. Therefore, a combination of complementary methods is always necessary for comprehensive chemical characterization.

Volatile and semivolatile organic compounds are typically analyzed by GC-MS Analysis, which provides both separation and structural identification. Meanwhile, nonvolatile polar compounds require HPLC Analysis with UV, fluorescence, or mass spectrometric detection. Furthermore, elemental impurities — including heavy metals — demand dedicated inorganic techniques aligned with USP General Chapter <232> Elemental Impurities requirements.

All methods must undergo validation — or at minimum rigorous verification — before use in regulatory studies. Specifically, accuracy, precision, linearity, and detection limits must demonstrate fitness for purpose. Our Method Development & Validation team builds defensible, regulatory-ready analytical methods tailored to each device’s chemical profile. Additionally, we reference peer-reviewed methodology from sources such as ScienceDirect – Analytical Methods to ensure our approaches reflect current scientific consensus.

For device materials requiring surface or structural characterization alongside chemical analysis, techniques such as FTIR Analysis and Raman Spectroscopy provide valuable complementary data. These methods identify polymer types, degradation products, and surface chemistry changes that may correlate with leachable generation. In addition, our Chemical & Elemental Characterization capabilities cover both organic and inorganic analytes within a single integrated workflow.

For a deeper look at how extractables and leachables testing relates to other device qualification activities, see our companion article on extractables vs leachables. Furthermore, manufacturers assessing material changes should also review our guidance on device material equivalency, since material substitutions trigger new E&L requirements. Understanding these interconnections early prevents costly late-stage surprises.

Advanced Analytical Techniques for Medical Device Extractables and Leachables

Modern E&L studies demand a broad analytical toolkit. No single instrument captures every chemical class, so laboratories combine complementary techniques to achieve comprehensive coverage. Furthermore, method selection must align with regulatory expectations and the specific chemistry of each device material.

Elemental Analysis — ICP-MS, ICP-OES, and AAS

Elemental impurities represent a critical subset of medical device extractables and leachables. Heavy metals such as lead, arsenic, cadmium, and chromium can leach from metal components, pigments, and processing aids. Consequently, inorganic analysis is mandatory for most device categories.

Inductively coupled plasma mass spectrometry (ICP-MS) offers the lowest detection limits — often in the sub-parts-per-trillion range — making it the preferred choice for permanent implants and blood-contacting devices. Meanwhile, ICP optical emission spectrometry (ICP-OES) handles higher-concentration matrices efficiently and provides excellent multi-element throughput. By contrast, atomic absorption spectrometry (AAS) suits single-element confirmation workflows where ICP instruments are unavailable.

All three techniques align with USP Elemental Impurities requirements and ISO 10993-18 guidance on inorganic characterization. Our Chemical & Elemental Characterization service integrates all three modalities for complete inorganic coverage.

Surface and Structural Characterization Techniques

Chemical migrants often originate at material surfaces. Therefore, surface-sensitive techniques add important mechanistic insight to E&L investigations. They help teams identify which surface chemistries or defects are driving leachable generation.

XPS Analysis quantifies elemental composition and chemical bonding states at the outermost material surface — typically the top 5–10 nm. This technique is particularly valuable for coated metals, surface-treated polymers, and oxide layers. In addition, XRF Analysis provides rapid semi-quantitative elemental screening across bulk and surface layers without sample destruction.

For structural identification of particulates or inorganic residues found in extracts, XRD Analysis determines crystalline phase composition. Moreover, NMR Spectroscopy provides definitive structural elucidation for unknown organic leachables — especially oligomers, degradation products, and polar nonvolatile compounds that GC-MS cannot resolve effectively.

Hyphenated and High-Resolution Mass Spectrometry

High-resolution mass spectrometry (HRMS) techniques — such as quadrupole time-of-flight (Q-TOF) and Orbitrap platforms — are increasingly central to E&L workflows. Specifically, HRMS enables confident structural assignment of unknown compounds at trace levels without requiring reference standards. This capability is invaluable when screening complex polymer extracts that contain dozens of unexpected migrants.

Liquid chromatography coupled with HRMS (LC-HRMS) handles nonvolatile, polar, and thermally labile compounds that GC-MS cannot address. Furthermore, this combination supports non-targeted screening — an approach that regulatory agencies increasingly expect for novel or complex devices. As a result, laboratories investing in HRMS capability deliver significantly more comprehensive analytical reports. Our Chemical & Analytical Testing team applies these advanced platforms to the most complex E&L challenges.

Research published through ScienceDirect continues to advance best practices in hyphenated MS techniques for pharmaceutical and medical device extractables work, providing the scientific community with evolving method frameworks.

Toxicological Risk Assessment of Identified Leachables

Identifying and quantifying leachables is only half the work. Ultimately, regulators require a toxicological risk assessment (TRA) that determines whether each identified compound poses an acceptable risk to patients. This assessment is where analytical chemistry and toxicology intersect.

Establishing Tolerable Intake and Safety Thresholds

ISO 10993-17 provides the methodology for deriving tolerable intake (TI) values for individual leachables. For compounds with existing toxicological databases, TI values come from no-observed-adverse-effect levels (NOAELs) and appropriate uncertainty factors. In addition, compounds with carcinogenic or genotoxic potential require more conservative threshold calculations.

The analytical evaluation threshold (AET) is a critical concept in this framework. Specifically, the AET is the analytical detection limit that must be achieved to ensure no clinically relevant leachable goes undetected. Compounds detected above the AET require full toxicological characterization; those below it may be excluded from further assessment. Our Biocompatibility & Toxicity Testing service integrates AET calculations directly into study design.

Handling Compounds Without Established Toxicology Data

Many extractables identified in device materials lack established toxicological data. Consequently, toxicologists must apply computational tools — such as quantitative structure-activity relationship (QSAR) modeling — to predict hazard potential. Furthermore, structure-activity relationship (SAR) analysis identifies structural alerts for genotoxicity, sensitization, and endocrine disruption.

For compounds with structural alerts or insufficient data, a conservative worst-case approach protects patient safety. Notably, this is an area where experienced toxicological expertise makes a decisive difference in achieving regulatory acceptance. Our Scientific & Technical Consulting team supports TRA development for compounds at every level of data availability.

E&L Testing Across Device Categories — Key Considerations

Different device categories present distinct E&L challenges. The materials involved, exposure routes, patient populations, and regulatory pathways all influence study design. Therefore, a one-size-fits-all approach rarely serves manufacturers well.

Implantable and Long-Term Contact Devices

Implantable devices — orthopedic implants, cardiovascular stents, neural interfaces — demand the most rigorous extractables and leachables characterization. Permanent patient contact means even low-level chronic exposures require careful evaluation. Furthermore, biomaterial degradation over implant lifetime can generate leachables that do not appear in short-term extraction studies.

Additionally, implantable devices often combine multiple materials — metals, polymers, ceramics, and biologic coatings — each contributing its own chemical profile. Our teams routinely conduct multi-material, multi-solvent extraction protocols for these complex assemblies. For context on reprocessed implants and reusable devices, our article on reusable medical device testing explores additional qualification requirements that intersect with E&L programs.

Drug-Device Combination Products

Drug-delivery systems — prefilled syringes, autoinjectors, inhaled drug-device combinations — face dual regulatory oversight from both drug and device perspectives. In these products, leachables can directly contaminate the drug formulation and affect both efficacy and patient safety. Consequently, the FDA and EMA impose especially stringent E&L requirements on combination products.

Leachables studies for combination products must use the actual drug formulation as the extraction medium where possible. Moreover, the analytical evaluation threshold for injectable and inhalation routes is far lower than for skin-contact devices — reflecting the direct systemic exposure these routes create. Our Method Development & Validation team designs formulation-compatible methods that meet both drug and device agency expectations.

Comparison of E&L Requirements by Device Category

Quality Assurance and Best Practices in E&L Programs

Analytical quality is the foundation of a defensible E&L program. Regulators scrutinize laboratory data closely, and any gap in quality can invalidate an otherwise thorough study. Therefore, best-practice quality systems are non-negotiable for E&L work intended for regulatory submission.

GLP Compliance and Laboratory Standards

Good Laboratory Practice (GLP) regulations govern non-clinical safety studies submitted to regulatory agencies. Specifically, GLP requires documented study protocols, calibrated instrumentation, traceable reference standards, and thorough raw data retention. Furthermore, GLP-compliant E&L studies carry significantly more regulatory weight than non-GLP work.

Even when full GLP compliance is not required, laboratories should follow ISO/IEC 17025 accreditation principles. Notably, accredited laboratories demonstrate documented competency, method validation, and external audit readiness. In addition, proficiency testing and inter-laboratory comparisons strengthen the defensibility of analytical results under regulatory scrutiny.

Documentation, Reporting, and Regulatory Submission Readiness

Complete documentation separates a regulatory-ready E&L report from a purely scientific exercise. Consequently, every study decision — solvent selection, extraction conditions, method validation parameters, and AET justification — must appear in the final report with clear scientific rationale. Reviewers expect to trace each analytical result back to raw data without ambiguity.

Furthermore, the report must clearly map leachables findings to the toxicological risk assessment conclusions. Presenting data in isolation — without toxicological context — is a common submission deficiency. Our article on FDA biocompatibility deficiencies highlights exactly how incomplete reporting triggers additional information requests. Ultimately, a well-structured, fully integrated E&L report is the most powerful tool a manufacturer has at the submission stage.

Early-Stage Planning Pays Off

Engaging E&L testing early — ideally during design and material selection — prevents the most costly problems. Specifically, discovering a high-risk leachable late in development may force material changes, redesign, or additional toxicology studies. By contrast, early screening identifies material risks when changes are still straightforward and inexpensive.

Additionally, manufacturers assessing material substitutions or suppliers should consult our guidance on device material equivalency, since even minor formulation changes can alter the extractables profile significantly. Our Scientific & Technical Consulting team helps manufacturers build proactive E&L strategies that align testing investment with actual regulatory risk.

Quick note: Regulators do not simply want analytical data — they want a coherent story linking material chemistry, analytical findings, and toxicological conclusions. Building that narrative from day one of your E&L program is the single most effective way to accelerate regulatory review and avoid deficiency letters.

Frequently Asked Questions About Medical Device E&L

What is the difference between extractables and leachables in medical devices?

Extractables are chemicals released from device materials under aggressive laboratory conditions designed to capture the worst-case chemical profile. Leachables, by contrast, are compounds that actually migrate into the patient or drug product during normal clinical use. In practice, leachables are typically a subset of extractables, though degradation products can sometimes appear only during real-world use. Both require identification, quantification, and toxicological assessment under ISO 10993-18.

Which analytical methods are most commonly used in E&L studies?

GC-MS is the primary tool for volatile and semivolatile organic compounds, while HPLC with mass spectrometric detection addresses nonvolatile polar compounds. ICP-MS and ICP-OES handle elemental impurities. Furthermore, FTIR, Raman, NMR, and XPS provide structural and surface characterization support. Comprehensive studies routinely deploy five or more complementary techniques to achieve full chemical coverage.

How does the analytical evaluation threshold (AET) work?

The AET is the minimum concentration that analytical methods must reliably detect in an E&L study. Specifically, it is calculated from the patient’s tolerable intake for a given compound, the device’s dose or contact parameters, and appropriate safety factors. Compounds detected above the AET require full toxicological evaluation. Those consistently below the AET may be excluded from further characterization, simplifying the overall assessment.

Do all medical devices require extractables and leachables testing?

Not all devices require the same depth of E&L testing, but most devices with direct patient contact require at least some chemical characterization under ISO 10993-18. Device contact nature and duration determine the rigor required. Consequently, permanent implants and drug-contacting devices face the most extensive requirements. By contrast, limited-contact skin devices may qualify for abbreviated assessments supported by material documentation.

When should manufacturers start E&L testing in the development timeline?

Manufacturers should initiate extractables screening as early as material selection — ideally before design freeze. Early testing identifies chemical risks while design changes remain practical and cost-effective. Furthermore, regulatory agencies expect E&L data to be available well before submission, since generating it under time pressure often leads to incomplete studies and deficiency letters. Building E&L into the design verification plan from day one is strongly recommended.

How do material changes affect an existing E&L program?

Any change in material formulation, supplier, or processing conditions can alter the extractables profile of a device component. Therefore, manufacturers must reassess E&L data whenever material changes occur. In some cases, a comparative extractables study may demonstrate equivalency. However, significant formulation changes typically require a new full characterization. Our guidance on device material equivalency outlines the decision framework for evaluating these changes systematically.

Conclusion

Medical device extractables and leachables testing sits at the intersection of analytical chemistry, toxicology, and regulatory science. Consequently, it demands rigorous planning, expert technique selection, and thorough documentation to produce results that satisfy regulators and protect patients. Shortcuts at any stage create compounding risk that surfaces — expensively — at the submission or post-market stage.

Furthermore, the analytical landscape continues to evolve. High-resolution mass spectrometry, non-targeted screening, and advanced computational toxicology are raising the standard for what comprehensive E&L characterization looks like. Manufacturers who invest in these capabilities now build a stronger regulatory position for current and future submissions.

At Materials Metric, our integrated Chemical & Analytical Testing and Biocompatibility & Toxicity Testing services provide end-to-end E&L support — from material inventory and extraction design through analytical execution, toxicological risk assessment, and regulatory report preparation. In addition, our Method Development & Validation team ensures every analytical method meets regulatory fitness-for-purpose requirements before a single sample is processed.

Whether you are preparing a first-in-class submission, managing a material change, or responding to an FDA deficiency, our team brings the scientific depth and regulatory experience your program needs. Contact Materials Metric today to discuss your E&L testing requirements and build a strategy that protects both your patients and your development timeline.

Related Posts from Materials Metric

Explore more insights from our team of materials scientists and analytical experts:

• Extractables vs leachables | Materials Metric | Chem Lab
• 510k testing requirements | Materials Metric | Compliance
• Supplier change risk assessment | Materials Metric
• Material change biocompatibility | Materials Metric

The post Medical device extractables and leachables | Materials Metric appeared first on Comprehensive Materials Testing and Analytical Services at Materials Metric.

Moreover, Extractables vs leachables describes two distinct but closely related categories of chemical compounds that can migrate from materials — such as packaging, medical devices, or drug container systems — into a product or biological environment. Understanding this difference is fundamental for any engineer, scientist, or quality professional working in pharmaceuticals, medical devices, or food contact materials at Materials Metric.

In addition, extractables are compounds forced out of a material under aggressive laboratory conditions. Leachables, by contrast, are the subset of those compounds that actually migrate into a product during normal use or storage. Therefore, extractables testing defines the chemical universe of potential migrants, while leachables testing confirms what patients or consumers actually encounter.

However, regulatory agencies — including the FDA and ISO — require both types of studies for many product categories. Consequently, a well-designed extractables and leachables (E&L) program protects patient safety, supports regulatory submissions, and reduces the risk of costly product recalls.

Key Takeaways

• Extractables are chemicals removed from a material under harsh, exaggerated laboratory conditions.
• Leachables are chemicals that migrate into a product during real-world use or storage.
• Leachables are generally a subset of extractables — not all extractables become leachables.
• Both studies are required by FDA, ISO 10993, and ICH Q3E guidelines for many regulated products.
• A structured E&L program protects patient safety and supports regulatory filings.
• Analytical techniques such as GC-MS Analysis, HPLC Analysis, and NMR Spectroscopy are central to E&L programs.
• Risk-based toxicological thresholds guide decisions about analytical reporting and patient safety.

Extractables vs Leachables: Extractables are chemical compounds isolated from a material under worst-case, exaggerated laboratory extraction conditions, while leachables are the specific compounds that migrate from that same material into a drug, device, or food product under actual conditions of use or storage — making leachables a patient-relevant subset of the broader extractable profile.

Key fact: Leachable compounds from drug container closure systems are a recognized contributor to drug product safety failures — making E&L testing one of the highest-priority analytical activities in pharmaceutical development and medical device qualification.

What Are Extractables? A Closer Look at the Definition

Therefore, extractables are chemical substances that migrate out of a material when exposed to solvents, elevated temperatures, or other aggressive extraction conditions in a laboratory setting. Importantly, these conditions exceed anything the material would experience during normal product use. The goal is to create a comprehensive chemical inventory of every compound the material could potentially release.

Furthermore, extractables studies are deliberately conservative. By using exaggerated conditions, analysts ensure they capture even low-abundance compounds that might otherwise go undetected. This broad-spectrum approach forms the foundation of any robust E&L program.

How Extractables Testing Works in Practice

Consequently, in a typical extractables study, a material sample contacts one or more extraction solvents — often chosen to mimic the polarity of the actual product. As a result, common solvents include water, ethanol, isopropanol, and simulated body fluids. Analysts then apply heat, extended contact time, or other stress conditions to maximize compound recovery.

Consequently, the resulting extract undergoes analysis using multiple complementary techniques. Specifically, GC-MS Analysis excels at identifying volatile and semi-volatile organics. Meanwhile, HPLC Analysis targets polar and non-volatile compounds. Together, these methods generate a detailed extractables profile.

Materials Commonly Evaluated for Extractables

A wide range of materials undergoes extractables assessment. These include polymer tubing, rubber stoppers, adhesives, coatings, medical device components, and pharmaceutical packaging. In addition, single-use bioprocessing equipment — such as bags, filters, and connectors — now receives significant attention due to its direct product contact.

Notably, the chemical complexity of modern polymers means extractables profiles can contain dozens to hundreds of individual compounds. Therefore, thorough analytical coverage is essential. Materials Metric’s Chemical Purity & Contaminant Screening service addresses this complexity directly.

What Are Leachables? Understanding Real-World Migration

Leachables are the compounds that actually transfer from a material into a product under normal or intended conditions of manufacture, storage, or use. By contrast to extractables, leachables reflect real patient or consumer exposure. Therefore, they carry direct safety and regulatory significance.

In pharmaceutical products, leachables appear in the drug formulation itself. For medical devices, they migrate into body fluids or tissues. Consequently, leachables data directly informs toxicological risk assessments and regulatory safety thresholds.

The Relationship Between Extractables and Leachables

Leachables are not an independent group — they come from the pool of extractables already identified. However, not every extractable becomes a leachable. Many compounds present under harsh extraction conditions never migrate at meaningful levels during real product use. Specifically, factors such as solubility, molecular weight, diffusion rate, and product contact time all control whether an extractable becomes a leachable.

Moreover, the extractables profile acts as a predictive tool. Regulators and scientists use it to anticipate which leachables are most likely to appear and at what levels. This relationship is central to understanding the difference between chemical characterization and biocompatibility in a broader regulatory context.

Leachables Testing Methods and Analytical Approaches

Leachables testing typically involves placing the final product — or a representative system — under actual use conditions for defined time periods. Analysts then examine the product itself, or simulated use extracts, for migrating compounds. Because concentrations are often very low, high-sensitivity analytical methods are essential.

For instance, FTIR Analysis supports compound identification when combined with chromatographic data. Similarly, NMR Spectroscopy confirms structural identity for unknown migrants at trace levels. Furthermore, Chemical & Elemental Characterization covers inorganic leachables, including metals from device components or process equipment.

Extractables vs Leachables: Key Differences Side by Side

Many professionals — especially those new to regulated industries — find the distinction between extractables and leachables confusing. However, the differences are clear once you examine them directly. The table below summarizes the most important distinctions.

Why Both Studies Are Necessary

Some teams ask whether extractables data alone is sufficient for regulatory submission. In most cases, the answer is no. Extractables establish the worst-case chemical inventory, but regulators require leachables data to confirm actual patient exposure levels. Therefore, both studies serve distinct and complementary roles.

For example, ISO 10993-18 Chemical Characterization explicitly requires a structured approach that includes both extractables and leachables assessment for medical devices. Similarly, the FDA’s guidance on container closure systems for pharmaceutical products mandates leachables data as part of drug product submissions.

Connecting E&L Data to Toxicological Risk

Identifying a compound is only the first step. Analysts must then determine whether the detected level poses a safety concern. This process — known as toxicological risk assessment — uses established thresholds such as the Analytical Evaluation Threshold (AET), the Safety Concern Threshold (SCT), and the Qualification Threshold (QT).

Furthermore, toxicological risk assessment links the chemical data from E&L studies to patient safety decisions. Importantly, this step requires both solid analytical data and expert toxicological interpretation. Materials Metric’s Biocompatibility & Toxicity Testing service integrates both capabilities for a seamless workflow.

Quick note: The Analytical Evaluation Threshold (AET) is not a safety threshold — it is a sensitivity target for analytical methods. Compounds detected above the AET require further toxicological evaluation, not automatic rejection. Understanding this distinction prevents unnecessary material rejections and costly program delays.

Regulatory Framework Governing Extractables vs Leachables

Multiple regulatory bodies and standards organizations govern E&L testing. Navigating this landscape requires a clear understanding of which guidelines apply to your specific product type. Moreover, requirements continue to evolve as agencies update their expectations.

The most commonly cited frameworks include FDA guidance documents, the ISO 10993-18 Chemical Characterization standard for medical devices, ICH Q3E (under development for drug products), and the PQRI (Product Quality Research Institute) guidelines for orally inhaled and nasal drug products. In addition, the USP General Chapter <232> Elemental Impurities addresses inorganic leachables in pharmaceutical products.

FDA Requirements for Container Closure Systems

The FDA’s 1999 guidance on container closure systems for packaging human drugs and biologics remains a cornerstone document. It requires manufacturers to demonstrate that packaging materials are safe and compatible with the drug product. Consequently, both extractables and leachables data appear in most drug applications for parenteral, ophthalmic, and inhalation products.

For orally inhaled products, the PQRI’s leachables guidance provides specific thresholds and study designs. Furthermore, the FDA increasingly expects E&L programs for topical products and other dose forms where direct material contact is significant. The Chemical & Analytical Testing services at Materials Metric support all of these submission types.

ISO 10993 and Medical Device Requirements

Medical device manufacturers must comply with the ISO 10993 series, specifically ISO 10993-18, which governs chemical characterization of device materials. This standard provides a risk-based framework for E&L studies. Notably, it aligns closely with FDA’s expectations for 510(k) submissions and pre-market approval (PMA) applications.

Under ISO 10993-18, manufacturers select extraction conditions based on device contact type — surface contact, external communicating, or implant — and contact duration. By contrast, pharmaceutical E&L programs focus more on the drug product formulation as the extraction medium. Understanding these differences is essential when designing a compliant study. The FDA chemical characterization review process provides additional context for device submissions specifically.

Elemental Impurities and Inorganic Leachables

Inorganic leachables — particularly heavy metals — receive specific regulatory attention. The USP General Chapter <232> Elemental Impurities sets permitted daily exposure (PDE) limits for 24 elemental impurities in drug products. Similarly, ICH Q3D provides the same framework at an international level.

Analytical techniques such as XRF Analysis and XPS Analysis support elemental screening of materials. Furthermore, inductively coupled plasma mass spectrometry (ICP-MS) provides the high-sensitivity quantitation needed for PDE-level compliance in final drug products. Materials Metric’s Chemical & Elemental Characterization service covers both screening and quantitative elemental analysis.

Advanced Analytical Techniques for Extractables vs Leachables Studies

Choosing the right analytical methods is critical to any successful E&L program. Furthermore, no single technique captures the full chemical diversity of modern materials. Therefore, most programs combine multiple orthogonal methods to maximize coverage and confidence.

Published research in ScienceDirect consistently highlights the value of multi-technique approaches in trace-level contaminant studies. Moreover, regulatory agencies expect analytical strategies that account for both organic and inorganic migrants across a wide concentration range.

Chromatographic Methods: GC-MS, HPLC, and LC-MS/MS

Gas chromatography-mass spectrometry remains the workhorse for volatile and semi-volatile organic extractables. It delivers excellent sensitivity, broad spectral library matching, and reliable quantitation. GC-MS Analysis is therefore standard in nearly every E&L program.

For polar and non-volatile compounds, HPLC Analysis provides complementary coverage. Coupled with mass spectrometry (LC-MS/MS), it achieves sub-parts-per-billion detection limits for targeted leachables monitoring. Consequently, this combination supports even the most demanding pharmaceutical and biologics submissions.

Elemental Analysis: ICP-MS, ICP-OES, and AAS

Inductively coupled plasma mass spectrometry (ICP-MS) is the gold standard for quantifying elemental impurities at trace and ultra-trace levels. It covers the full periodic table and meets the sensitivity requirements of USP Elemental Impurities guidance and ICH Q3D.

ICP optical emission spectrometry (ICP-OES) offers a cost-effective alternative for elements present at higher concentrations. Meanwhile, atomic absorption spectrometry (AAS) provides targeted single-element quantitation when screening for specific metals. Materials Metric’s Chemical & Elemental Characterization service deploys all three techniques based on project requirements.

Spectroscopic and Structural Identification Tools

Structural confirmation of unknown migrants requires spectroscopic tools beyond chromatography. FTIR Analysis rapidly identifies functional groups and polymer fragments in extracts. Additionally, Raman Spectroscopy provides complementary structural data — particularly for inorganic and carbon-based compounds.

For unambiguous structural elucidation, NMR Spectroscopy remains the definitive tool. It identifies molecular connectivity and confirms compound identity independently of spectral libraries. Furthermore, surface-sensitive techniques such as XPS Analysis characterize elemental states and surface chemistry — especially useful for metal device components.

Method Development and Validation for E&L Programs

Analytical methods used in regulated E&L studies must meet defined performance criteria. Specifically, methods require validation for specificity, linearity, accuracy, precision, and detection limits. This ensures results are defensible during regulatory review.

Materials Metric’s Method Development & Validation service builds and qualifies fit-for-purpose methods for both extractables screening and targeted leachables quantitation. Importantly, a validated method aligned to the AET ensures that no safety-relevant compound falls below the analytical detection limit.

Industry-Specific Applications of Extractables vs Leachables Testing

E&L requirements vary significantly across industries. However, the underlying science remains consistent — identify what migrates, quantify it, and assess the risk. The sections below outline how different sectors apply extractables and leachables principles in practice.

Pharmaceuticals and Biologics

Drug product manufacturers face the most developed regulatory framework for E&L testing. Container closure systems, primary packaging, and drug delivery devices all require assessment. In particular, parenteral, inhalation, and ophthalmic products receive the highest scrutiny because they deliver drugs directly into the body.

Biologics present additional complexity. Protein-based drugs are sensitive to leachables that can cause aggregation, degradation, or immunogenic responses. Therefore, E&L programs for biologics often include functional impact studies alongside chemical identification. The Chemical & Analytical Testing team at Materials Metric supports pharmaceutical clients across all dose form categories.

Medical Devices and Implants

Medical device E&L programs operate under the ISO 10993-18 framework. Device manufacturers must characterize all materials in patient contact and assess migration risk based on contact type and duration. Consequently, implantable devices face the most rigorous requirements.

Additives such as plasticizers, stabilizers, antioxidants, and colorants are common extractables targets in device polymers. Furthermore, metallic implants may release corrosion products or wear debris over time — making long-term leachables monitoring essential. For complex device systems, the reusable medical device testing framework adds another layer of E&L consideration.

Single-Use Bioprocessing Systems

Single-use technology — including bioreactor bags, tubing, and filter assemblies — has transformed biologics manufacturing. However, these polymer-intensive systems introduce significant E&L risk at the drug substance level. Regulators now expect comprehensive extractables profiles for all single-use components in contact with drug intermediates.

Industry consortia such as BPOG (BioPhorum Operations Group) have published standardized extractables testing protocols for single-use systems. Moreover, manufacturers increasingly require supplier-generated extractables data before qualifying new components. Materials Metric supports both supplier-side testing and manufacturer-side qualification programs.

Food Contact Materials and Consumer Products

E&L principles extend beyond regulated pharmaceuticals and devices. Food packaging, beverage containers, and consumer product packaging all face migration testing requirements under regulations such as EU Regulation 10/2011 and FDA’s food contact substance notification program.

In these contexts, leachables testing assesses whether packaging components migrate into food or beverages under storage and heating conditions. Similarly, chemical purity evaluation under Materials Metric’s Chemical Purity & Contaminant Screening service applies directly to food contact compliance studies.

Best Practices for Designing a Robust E&L Program

A well-designed E&L program saves time and cost while satisfying regulators. However, poorly planned studies often generate insufficient data — forcing expensive repeat testing. Therefore, upfront investment in program design is always worthwhile.

Start with a Material Risk Assessment

Begin every E&L program with a systematic material risk assessment. Identify all components in contact with the product, rank them by contact type and duration, and prioritize materials with the highest migration potential. This step aligns with the risk-based approach required by ISO 10993-18 and FDA guidance.

Notably, early engagement with regulatory strategy — through Materials Metric’s Scientific & Technical Consulting service — helps teams avoid common design errors. For instance, selecting inappropriate extraction solvents or insufficient contact times can invalidate an entire study.

Apply a Tiered Analytical Approach

Most successful E&L programs use a tiered strategy. The first tier focuses on broad-spectrum screening to identify all compounds above the AET. The second tier quantifies confirmed extractables using validated methods. The third tier correlates extractables data with leachables observed in product stability studies.

This structure prevents unnecessary analytical work at higher tiers for compounds eliminated at the screening stage. Consequently, costs remain manageable without sacrificing scientific rigor. The following list summarizes the core tiers:

• Tier 1 — Screening: Broad-spectrum extraction and identification using GC-MS, HPLC-UV, and ICP-MS.
• Tier 2 — Quantitation: Validated targeted methods for confirmed extractables above the AET.
• Furthermore, Tier 3 — Leachables correlation: Product-contact leachables studies linked to stability testing programs.

Document, Document, Document

Regulatory reviewers scrutinize E&L study documentation carefully. Every extraction condition, analytical method, instrument calibration, and data interpretation decision must be recorded. Furthermore, chain-of-custody records for materials and samples provide essential traceability.

Importantly, studies conducted under good laboratory practice (GLP) or at ISO 17025-accredited laboratories carry greater weight in regulatory submissions. Therefore, selecting a qualified testing partner with documented quality systems matters as much as the analytical techniques themselves.

Integrate Toxicological Evaluation Early

Many teams treat toxicological risk assessment as a final step — conducted only after all analytical data are available. However, integrating a toxicologist early in the program design improves efficiency significantly. Early input defines the AET, shapes extraction strategies, and identifies compounds of concern before costly studies begin.

Materials Metric’s Biocompatibility & Toxicity Testing service pairs analytical chemists with toxicological experts. This integrated model streamlines the path from raw data to a defensible safety conclusion. Additionally, it supports the toxicological risk assessment documentation required for regulatory submissions.

Quick note: Always align your extractables study design with the intended leachables monitoring plan before any laboratory work begins. Mismatched solvent systems or extraction conditions between the two studies are a leading cause of regulatory questions and program delays.

Frequently Asked Questions About Extractables vs Leachables

What is the main difference between extractables and leachables?

Extractables are chemicals removed from a material under exaggerated laboratory conditions. Leachables are the subset of those chemicals that migrate into a product under real use or storage conditions. Therefore, leachables represent actual patient or consumer exposure, while extractables define the worst-case chemical inventory.

Are leachables always a subset of extractables?

In the vast majority of cases, yes. Regulators and industry guidance documents treat leachables as a subset of extractables. However, rare situations exist where a leachable forms through a reaction with the product formulation — making it a degradation product rather than a direct extractable. Consequently, thorough leachables monitoring sometimes reveals unexpected compounds not present in the extractables profile.

Which regulatory guidelines govern E&L testing?

Several frameworks apply depending on product type. For pharmaceutical products, relevant guidelines include FDA container closure guidance, PQRI leachables guidance, and ICH Q3E. For medical devices, ISO 10993-18 is the primary standard. In addition, USP Elemental Impurities guidance applies to inorganic leachables in drug products.

What is the Analytical Evaluation Threshold (AET)?

The AET is a calculated method sensitivity target — not a safety limit. It defines the minimum concentration at which an analytical method must reliably detect and quantify compounds. Specifically, the AET derives from the Safety Concern Threshold (SCT) and accounts for the maximum daily dose of the product. Compounds detected above the AET require further toxicological evaluation.

How long does an E&L study typically take?

Timeline varies based on product type, number of materials, and study design complexity. A focused extractables screening study may complete in four to eight weeks. By contrast, full leachables programs tied to product stability studies can span twelve to twenty-four months. Early planning and well-defined study protocols reduce delays significantly.

Can a material’s extractables profile change over time?

Yes, and this is an important consideration. Manufacturing changes, supplier changes, or material aging can shift a material’s extractables profile. Notably, new additives or processing aids introduced by a supplier may appear without prior notice. Therefore, ongoing extractables monitoring — especially following any material change — is a sound quality practice.

Conclusion

Understanding the distinction between extractables vs leachables is foundational to safe product development across pharmaceuticals, medical devices, and regulated materials. Furthermore, a well-executed E&L program protects patients, satisfies regulators, and builds long-term confidence in your materials and packaging systems.

From broad-spectrum extractables screening to targeted leachables monitoring, the analytical journey requires careful planning, validated methods, and expert toxicological interpretation. Moreover, as regulatory expectations continue to evolve, keeping your E&L program current demands ongoing investment in both science and strategy.

Materials Metric brings together advanced instrumentation, experienced analytical chemists, and regulatory expertise under one roof. Consequently, our team supports E&L programs from initial material risk assessment through final regulatory submission — regardless of product type or regulatory jurisdiction.

Whether you need a rapid extractables screen, a validated leachables monitoring method, or full toxicological risk assessment support, we are ready to help. To discuss your specific project needs and learn how Materials Metric can support your E&L program, please contact Materials Metric today. Our team will respond promptly to scope your requirements and recommend the right analytical approach for your program.

Related Posts from Materials Metric

Explore more insights from our team of materials scientists and analytical experts:

• 510k testing requirements | Materials Metric | Compliance
• Supplier change risk assessment | Materials Metric
• Material change biocompatibility | Materials Metric
• Chemical characterization vs biocompatibility | Materials Metric

The post Extractables vs leachables | Materials Metric | Chem Lab appeared first on Comprehensive Materials Testing and Analytical Services at Materials Metric.

Chemical characterization vs biocompatibility represents one of the most important distinctions in medical device development: chemical characterization identifies what chemical substances a material contains or releases, while biocompatibility testing determines whether those substances cause harm to living tissue. Together, these two disciplines form the backbone of Materials Metric’s device safety evaluation framework. Understanding how they differ — and how they work together — helps engineers, regulatory teams, and quality managers make smarter, faster compliance decisions.

Furthermore, many professionals treat these two processes as interchangeable. However, they serve fundamentally different purposes within the ISO 10993 biological evaluation framework. Moreover, chemical characterization answers the question “What is in this material?” Biocompatibility testing then answers “Is that substance safe for patients?” Consequently, chemical characterization typically comes first, feeding its data directly into the biocompatibility risk assessment process.

In addition, for medical device manufacturers navigating FDA submissions or CE marking, understanding where chemical characterization ends and biocompatibility begins can save months of rework. Moreover, regulators increasingly expect manufacturers to use chemical characterization data to justify whether biological tests are even necessary. This approach, called risk-based biological evaluation, reduces animal testing and accelerates timelines — but only when teams understand each method’s role and limitations.

Key Takeaways

• Chemical characterization identifies chemical substances in or released by a material; biocompatibility testing evaluates whether those substances harm living systems.
• ISO 10993-18 governs chemical characterization; ISO 10993-1 governs the overall biological evaluation framework.
• Chemical characterization data can reduce or eliminate the need for certain in vitro or in vivo biocompatibility tests.
• Both disciplines are complementary — not competing — and together they form a complete biological risk assessment.
• Regulators expect manufacturers to document the relationship between chemical findings and biological safety decisions.
• Partnering with an experienced laboratory accelerates submissions and reduces costly deficiency responses.

Chemical characterization vs biocompatibility: Chemical characterization is the analytical process of identifying and quantifying chemical substances present in or released from a material or device, while biocompatibility assessment evaluates whether those identified substances or the material as a whole poses an unacceptable biological risk to patients or users — together, these two processes constitute a complete ISO 10993-compliant biological safety evaluation.

However, Key fact: According to FDA feedback trends, incomplete or missing chemical characterization data is among the leading causes of biocompatibility-related deficiency letters for medical device 510(k) and PMA submissions. Learn more in our article on FDA biocompatibility deficiencies.

What Is Chemical Characterization for Medical Devices?

Therefore, chemical characterization is the systematic process of identifying, quantifying, and evaluating chemical substances associated with a medical device or its constituent materials. Consequently, regulators define it formally under ISO 10993-18 Chemical Characterization, which outlines how to plan, conduct, and document chemical analysis. Furthermore, the FDA’s 2023 guidance aligns closely with this standard, making ISO 10993-18 the international benchmark for device manufacturers worldwide.

As a result, in practice, chemical characterization covers two primary categories: extractables and leachables. Specifically, extractables are chemical compounds released from a material under exaggerated laboratory conditions. Leachables, by contrast, are substances that migrate into a patient-contacting environment under actual use conditions. Both categories require thorough analytical investigation before a device reaches market.

Why Extractables and Leachables Matter

Notably, extractables and leachables studies provide the chemical data that regulators and toxicologists need to assess patient risk. Importantly, without this data, a biological evaluation remains incomplete and vulnerable to challenge. Specifically, FDA reviewers expect manufacturers to document what chemicals could potentially reach a patient and at what exposure levels.

Meanwhile, analytical techniques commonly used in extractables and leachables studies include GC-MS Analysis, HPLC Analysis, and NMR Spectroscopy. By contrast, each method targets different chemical classes — volatile organics, semi-volatiles, involatile compounds, and inorganic elements. Therefore, a comprehensive extractables study typically employs multiple orthogonal analytical methods rather than relying on any single technique.

Elemental impurities also form a critical part of chemical characterization. For drug-device combination products, USP General Chapter <232> Elemental Impurities sets permitted daily exposure (PDE) limits for toxic metals. Materials Metric’s Chemical & Elemental Characterization services address these requirements with high-sensitivity elemental analysis techniques.

Key Analytical Methods in Chemical Characterization

Selecting the right analytical toolkit is essential for generating regulatory-quality chemical characterization data. Different material types and device contact durations call for different analytical strategies. For instance, polymeric materials often require FTIR Analysis and Raman Spectroscopy to identify polymer composition, additives, and degradation products.

Surface characterization techniques add another layer of information. XPS Analysis reveals elemental composition and chemical bonding states at a material’s outermost surface — a particularly valuable tool for implantable devices. Additionally, XRF Analysis provides rapid, non-destructive bulk elemental screening across a wide range of elements.

Morphological characterization also plays a supporting role, particularly for particulate-releasing devices. SEM Analysis and TEM Analysis help teams visualize particle size, shape, and surface features. Consequently, these techniques support both chemical characterization and downstream toxicological risk assessments for particulate hazards.

The table below summarizes common chemical characterization techniques and their primary applications in device testing:

What Is Biocompatibility Testing for Medical Devices?

Biocompatibility testing evaluates whether a medical device or its constituent materials cause harmful biological responses when in contact with the human body. ISO 10993-1 defines the overall framework, categorizing tests by device contact type (surface, externally communicating, or implant) and duration (limited, prolonged, or permanent). Importantly, not every device requires every biological test — the standard encourages a risk-based approach informed by chemical characterization data.

Biological endpoints evaluated in biocompatibility programs include cytotoxicity, sensitization, irritation, systemic toxicity, genotoxicity, carcinogenicity, and reproductive toxicity, among others. Each endpoint addresses a specific biological hazard pathway. Furthermore, the selection of relevant endpoints depends on the device’s intended use, body contact, and duration of exposure.

In Vitro vs. In Vivo Biocompatibility Tests

Biocompatibility tests fall into two broad categories: in vitro (cell-based, laboratory) and in vivo (animal-based) studies. In vitro cytotoxicity testing — often the first test performed — uses cell cultures to screen for cell-killing substances. These studies align with ISO 10993-5 and offer a rapid, cost-effective first-pass biological screen.

In vivo tests, by contrast, involve animal models and provide information on systemic, implantation, or sensitization responses. However, regulators now strongly encourage manufacturers to minimize animal use by leveraging chemical characterization and in vitro data first. Consequently, a well-executed chemical characterization program can reduce or even eliminate certain in vivo testing requirements. Our article on risk-based biocompatibility testing explores this strategy in detail.

How Biological Evaluation Plans Guide Testing Decisions

A Biological Evaluation Plan (BEP) is the strategic document that maps out which biocompatibility tests a device requires — and justifies why certain tests can be waived. Regulators expect this document before testing begins, not after. Therefore, preparing a thorough BEP early in development is a critical success factor for any device program.

The BEP draws heavily on chemical characterization data. For instance, if extractables data shows that all chemical substances fall below established toxicological thresholds, a manufacturer can document a scientifically justified rationale to waive systemic toxicity testing. Moreover, material equivalency arguments — comparing a new device material to one with an established biocompatibility record — can further streamline the evaluation. See our related post on device material equivalency for more on this strategy.

Materials Metric’s Biocompatibility & Toxicity Testing team can help manufacturers develop defensible BEPs that reflect current FDA and ISO 10993 expectations.

Quick note: The FDA increasingly scrutinizes biological evaluation plans that rely solely on published literature or material supplier data sheets, without supporting chemical characterization data generated under controlled laboratory conditions. Generating your own extractables data — specific to your device’s geometry, materials, and processing — strengthens your submission significantly.

Chemical Characterization vs Biocompatibility: Key Differences Explained

Understanding the difference between chemical characterization and biocompatibility testing clarifies how each discipline contributes to device safety. Both processes aim to protect patients, but they approach that goal from different scientific angles. The following comparison highlights the most important distinctions teams need to understand.

Scope, Purpose, and Regulatory Basis

Chemical characterization focuses on identifying and quantifying chemical entities. Its regulatory basis is ISO 10993-18 Chemical Characterization, supplemented by ISO 10993-17 for toxicological risk assessment. Biocompatibility testing, by contrast, assesses biological responses and operates under ISO 10993-1 as the overarching framework, with specific endpoints addressed by ISO 10993-5 through ISO 10993-23 and beyond.

Furthermore, chemical characterization is fundamentally analytical — it generates data about substances. Biocompatibility assessment is fundamentally interpretive and biological — it evaluates whether those substances (or the device as a whole) cause harm. Therefore, these two disciplines require different scientific expertise, equipment, and regulatory documentation strategies.

Timing Within the Development Lifecycle

Chemical characterization typically occurs earlier in the device development process. Teams conduct it during material selection, process development, and pre-submission stages. Specifically, early chemical data allows engineers to reformulate materials, switch suppliers, or adjust processing conditions before biological testing begins.

Biocompatibility testing generally follows chemical characterization, though some in vitro screens may run in parallel. By the time a full biological evaluation plan is executed, chemical characterization data should already be available to inform testing decisions. This sequential logic is central to the risk-based framework outlined in ISO 10993-1 and strongly reinforced in FDA guidance. Our detailed article on FDA chemical characterization review explains what reviewers specifically look for in submission packages.

How Chemical Data Informs Biological Decisions

Chemical characterization data directly shapes which biocompatibility tests a device needs. If a thorough extractables study identifies no substances above toxicological concern thresholds, a manufacturer can document a scientific justification to waive certain biological tests. This approach saves time, reduces cost, and avoids unnecessary animal studies.

By contrast, if chemical characterization identifies substances of high concern — such as residual monomers, processing aids, or heavy metals — targeted biological testing becomes essential. For example, a device leaching a known sensitizer would trigger sensitization testing under ISO 10993-10 regardless of other data. Additionally, unexpected chemical findings can prompt further investigation using Chemical Purity & Contaminant Screening to fully characterize impurities before the toxicological risk assessment proceeds.

Experienced analytical teams and toxicologists need to collaborate closely throughout this process. Materials Metric’s Chemical & Analytical Testing services are specifically designed to generate the high-quality, regulatory-grade data that toxicologists and biological evaluators need to draw defensible conclusions. Explore additional research perspectives through resources such as PubMed Central – Trace Metals Review and peer-reviewed literature indexed in ScienceDirect – Analytical Methods.

Advanced Analytical Techniques Supporting Chemical Characterization vs Biocompatibility Decisions

Advanced analytical methods provide the backbone of rigorous chemical characterization programs. Selecting the right technique ensures that chemical findings are accurate, defensible, and directly useful for biocompatibility risk assessments. Furthermore, method selection must align with the specific chemical classes expected, the detection limits required, and the regulatory framework in scope.

ICP-MS and ICP-OES for Elemental Analysis

Inductively coupled plasma mass spectrometry (ICP-MS) delivers exceptional sensitivity for toxic metal detection. It quantifies elements at parts-per-trillion levels — making it the preferred method for device extracts where elemental impurities may be present at trace concentrations. Consequently, ICP-MS directly supports compliance with USP Elemental Impurities requirements and ISO 10993-18 elemental analysis protocols.

Inductively coupled plasma optical emission spectrometry (ICP-OES) offers a complementary approach. It handles higher concentration ranges and provides simultaneous multi-element detection across dozens of elements. For instance, screening a stainless steel implant for nickel, chromium, and cobalt leaching is a typical ICP-OES application in device biocompatibility programs.

Atomic Absorption Spectrometry in Device Testing

Atomic absorption spectrometry (AAS) targets specific elements with excellent precision. Unlike ICP techniques, AAS analyzes one element at a time — making it most efficient when a small, defined set of metals needs confirmation. Moreover, graphite furnace AAS (GF-AAS) achieves detection limits approaching those of ICP-MS for elements such as lead, cadmium, and arsenic.

Together, ICP-MS, ICP-OES, and AAS form a powerful elemental characterization toolkit. Regulatory-grade programs often use these methods in combination, cross-validating results to ensure data integrity. Materials Metric’s Chemical & Elemental Characterization team routinely selects and validates the most appropriate elemental technique for each specific device and material type.

Thermal and Structural Techniques Supporting Biocompatibility Decisions

Thermal analysis methods round out the characterization toolkit for polymeric and composite device materials. DSC Testing identifies phase transitions, crystallinity, and thermal stability — properties that directly influence how a polymer leaches chemicals under physiological conditions. Specifically, a material with a low glass transition temperature may release plasticizers or additives more readily at body temperature.

Structural and diffraction methods also contribute important information. XRD Analysis identifies crystalline phases in metallic alloys, ceramics, and coatings. Understanding phase composition helps predict corrosion behavior and long-term chemical stability — factors that directly influence leachable profiles and, ultimately, biocompatibility risk. Additionally, well-validated methods ensure that these data points hold up under regulatory scrutiny, which is why robust Method Development & Validation is essential for every characterization program.

Industry Applications: Where Chemical Characterization vs Biocompatibility Decisions Matter Most

The interplay between chemical characterization and biocompatibility extends well beyond medical devices. Numerous industries rely on the same foundational principles to protect human health, ensure product safety, and meet regulatory requirements. Understanding industry-specific applications helps teams identify the most relevant analytical strategy for their context.

Medical Devices and Pharmaceutical Packaging

Medical devices represent the most heavily regulated application of chemical characterization vs biocompatibility evaluation. Every implantable, blood-contacting, or mucosal-contact device must undergo biological evaluation under ISO 10993-1. Consequently, extractables and leachables studies are routine requirements for device manufacturers submitting 510(k), De Novo, or PMA applications to the FDA.

Pharmaceutical packaging presents closely related challenges. Primary packaging — vials, syringes, blister packs, and closures — contacts drug products directly and can leach chemicals into formulations. Therefore, extractables characterization of packaging materials is critical both for drug safety and for regulatory submissions under ICH Q3C (residual solvents) and ICH Q3D (elemental impurities). Our Wet Chemistry & Classical Analytical Methods services support these applications with well-established, regulatory-accepted techniques.

Aerospace and High-Performance Materials

Aerospace applications demand chemical characterization for different reasons. Material composition must be precisely controlled to ensure structural integrity, corrosion resistance, and compatibility with harsh operating environments. Furthermore, coatings, adhesives, and sealants used in aerospace assemblies must meet strict composition specifications.

Biocompatibility concerns arise in aerospace when materials contact crew members’ skin or breathing air — for example, cabin materials, oxygen system components, and life-support equipment. In such cases, outgassing characterization (identifying volatile organic compounds released by materials) functions as an aerospace equivalent of extractables testing. Similarly, toxicological assessment of identified compounds mirrors the biocompatibility risk assessment process used in medical device evaluation.

Environmental and Consumer Product Safety

Environmental laboratories apply chemical characterization principles to assess contaminant profiles in soil, water, and air samples. Regulatory frameworks such as EPA methods require sensitive, validated analytical techniques to quantify trace pollutants. Notably, many analytical methods used in device extractables studies — GC-MS, ICP-MS, HPLC — are direct adaptations of environmental monitoring techniques.

Consumer product safety programs also rely on chemical characterization to screen for restricted substances. For example, REACH compliance for chemicals in articles sold in the EU requires identification and quantification of substances of very high concern (SVHC). Consequently, Chemical Purity & Contaminant Screening services support both medical and non-medical clients navigating these requirements. Resources such as ScienceDirect provide peer-reviewed methodology references for both environmental and biomedical analytical applications.

Quality Assurance and Best Practices for Chemical Characterization vs Biocompatibility Programs

High-quality data is the foundation of every defensible biocompatibility package. Poor analytical practices — inadequate method validation, inappropriate extraction conditions, or incomplete reporting — are among the most common reasons regulators issue deficiency responses. Therefore, embedding quality assurance throughout the characterization process is not optional; it is essential.

Method Validation and Data Integrity

Every analytical method used in a regulatory submission must be appropriately validated. Validation confirms that a method is accurate, precise, specific, and sensitive enough to detect substances at concentrations that matter toxicologically. Specifically, method validation for extractables studies typically includes assessment of linearity, limits of detection (LOD), limits of quantitation (LOQ), recovery, and matrix effects.

Data integrity practices — including audit trails, calibration records, and instrument qualification — ensure that analytical results are traceable and reproducible. Furthermore, laboratories operating under ISO/IEC 17025 accreditation provide an additional layer of assurance that methods meet international quality standards. Materials Metric’s Method Development & Validation team develops fit-for-purpose analytical methods that satisfy both regulatory expectations and scientific rigor.

Extraction Condition Design and Worst-Case Scenarios

Choosing the right extraction conditions is a critical quality decision in any chemical characterization program. ISO 10993-18 requires that extraction conditions reflect realistic or exaggerated worst-case patient exposure. For instance, extraction solvents should mimic the chemical polarity of body fluids, and temperature or time conditions should accelerate release to ensure that all potentially leachable substances are detected.

Poorly chosen extraction conditions can lead to false negatives — substances present in a material go undetected because the extraction failed to release them. This outcome is particularly dangerous in biological evaluation because it creates an artificially clean chemical profile that does not represent true patient risk. Therefore, experienced analytical chemists must design extraction protocols thoughtfully, informed by material type, device contact conditions, and intended use.

Integrating Toxicological Risk Assessment

Chemical characterization data alone does not constitute a complete biological evaluation. A qualified toxicologist must review chemical findings, assess each identified substance against established toxicological thresholds, and generate a formal toxicological risk assessment (TRA). This TRA then feeds directly into the biological evaluation report (BER).

Toxicological thresholds — such as the threshold of toxicological concern (TTC) and substance-specific tolerable intake (TI) values — provide the scientific framework for deciding whether identified chemicals pose a risk. Moreover, if a substance lacks published toxicological data, a qualified toxicologist must derive a safety threshold from available in vitro or structural analog data. Materials Metric’s Scientific & Technical Consulting services provide expert toxicological and regulatory guidance throughout this process.

Quick note: Regulatory agencies expect chemical characterization reports to include full analytical method details, instrument parameters, calibration data, and raw spectra or chromatograms. Submitting summary tables without supporting raw data is a frequent source of FDA information requests. Always retain complete analytical documentation in your technical file.

Frequently Asked Questions About Chemical Characterization vs Biocompatibility

Is chemical characterization required before biocompatibility testing?

Yes — regulatory guidance strongly recommends completing chemical characterization before finalizing a biocompatibility testing plan. Specifically, ISO 10993-18 and ISO 10993-1 together establish that chemical data should inform which biological endpoints require testing. Moreover, FDA reviewers expect a documented rationale linking chemical findings to biological test selection decisions.

Can chemical characterization data replace biocompatibility testing entirely?

In some cases, yes — but only partially, and only with rigorous scientific justification. If chemical characterization shows that all identified substances fall below established toxicological thresholds, certain biological tests may be waived. However, most regulatory submissions still require at least cytotoxicity data as a baseline biological screen. Additionally, contact type and duration heavily influence which tests cannot be waived regardless of chemical data.

What is a threshold of toxicological concern (TTC), and why does it matter?

A threshold of toxicological concern (TTC) is a conservative exposure level below which a chemical is considered unlikely to pose a significant risk to human health — even without substance-specific toxicological data. In practice, if a leachable substance is quantified below its applicable TTC, a toxicologist can document a risk-based justification to waive targeted biological testing for that substance. Consequently, TTC application is a powerful tool for streamlining biocompatibility programs without compromising patient safety.

How do extractables differ from leachables in a chemical characterization context?

Extractables are chemicals released from a material under exaggerated laboratory conditions — typically aggressive solvents, elevated temperatures, and extended contact times. Leachables, by contrast, are chemicals that actually migrate under real-world use conditions — normal solvents, body temperature, and actual contact durations. Therefore, extractables studies provide a comprehensive worst-case chemical inventory, while leachables studies confirm which substances a patient realistically encounters. Both data sets are necessary for a complete risk assessment.

Which ISO 10993 parts govern chemical characterization vs biocompatibility testing?

Chemical characterization falls primarily under ISO 10993-18 (chemical characterization of materials) and ISO 10993-17 (toxicological risk assessment). Biocompatibility testing operates under ISO 10993-1 as the overarching framework, with specific biological endpoints addressed by parts such as ISO 10993-5 (cytotoxicity), ISO 10993-10 (sensitization), ISO 10993-11 (systemic toxicity), and ISO 10993-23 (irritation). Furthermore, ISO 10993-12 covers sample preparation and reference materials applicable to both chemical and biological test programs.

When should a manufacturer engage a testing laboratory for chemical characterization and biocompatibility support?

Ideally, manufacturers engage an experienced laboratory at the earliest stages of device development — during material selection and design finalization. Early engagement allows the analytical team to design an efficient, fit-for-purpose chemical characterization program. Furthermore, early involvement of a Scientific & Technical Consulting partner helps avoid downstream surprises that could delay regulatory submission or trigger costly design changes. Materials Metric’s Chemical & Analytical Testing team is available to advise on program design from the earliest project stages.

Conclusion

Understanding the distinction between chemical characterization vs biocompatibility is fundamental for any team developing, manufacturing, or evaluating medical devices or patient-contacting materials. Chemical characterization identifies what is in a material; biocompatibility assessment determines whether those findings pose a biological risk. Together, these two disciplines form a complete, regulatory-grade safety evaluation — and neither can substitute for the other.

Moreover, the quality of chemical characterization data directly determines the strength of every downstream biological safety decision. Poorly designed extractables studies, unvalidated methods, or incomplete reporting create vulnerabilities that regulators will identify. By contrast, a well-executed chemical characterization program — built on orthogonal analytical techniques, validated methods, and expert toxicological interpretation — gives manufacturers the confidence to make defensible biocompatibility decisions quickly.

As regulatory expectations continue to evolve under updated FDA guidance and ISO 10993 standards, staying ahead requires both scientific depth and regulatory fluency. Ultimately, teams that invest in thorough chemical characterization early in development experience fewer deficiency letters, shorter review timelines, and stronger submissions overall.

Materials Metric provides comprehensive support across the full chemical characterization and biocompatibility evaluation workflow — from Chemical & Analytical Testing and Chemical & Elemental Characterization to Biocompatibility & Toxicity Testing and expert Scientific & Technical Consulting. Our team brings deep analytical expertise, regulatory knowledge, and a commitment to data quality that submission packages demand.

Ready to build a stronger, more efficient biological evaluation program? Contact Materials Metric today to discuss your chemical characterization or biocompatibility testing needs with our expert team.

Related Posts from Materials Metric

Explore more insights from our team of materials scientists and analytical experts:

• Reusable medical device testing | Materials Metric
• ISO 10993 existing data | Materials Metric | Compliance
• FDA biocompatibility deficiencies | Materials Metric
• Deformulation analysis | Materials Metric | Deformulation

The post Chemical characterization vs biocompatibility | Materials Metric appeared first on Comprehensive Materials Testing and Analytical Services at Materials Metric.

Key Takeaways

• An FDA chemical characterization review evaluates the chemical identity, purity, and safety of materials used in medical devices and pharmaceutical products.
• Regulatory frameworks — including ISO 10993-18 Chemical Characterization and FDA guidance — define clear requirements for manufacturers.
• Extractables and leachables (E&L) studies are a core component of FDA submissions for drug-contact and device materials.
• Elemental impurity testing under USP General Chapter <232> Elemental Impurities is mandatory for many pharmaceutical products.
• Early-stage chemical characterization reduces late-cycle regulatory risk and accelerates time to market.
• Partnering with an accredited laboratory ensures data quality, method validity, and FDA submission readiness.

What Is an FDA Chemical Characterization Review?

A FDA chemical characterization review is the formal regulatory process by which the U.S. Food and Drug Administration evaluates chemical data submitted by manufacturers of medical devices, pharmaceutical products, and combination products. At Materials Metric, we help companies build and defend these data packages every day. Ultimately, understanding what the FDA expects — and why — is the first step toward a successful submission.

Chemical characterization means systematically identifying and quantifying the chemical entities present in a material or product. Specifically, these entities include raw material constituents, processing aids, degradation products, and potential extractables. Consequently, the FDA uses this data to assess patient safety risk before granting market authorization.

Furthermore, the scope of an FDA chemical characterization review extends across product categories. Medical devices, drug-device combination products, pharmaceutical packaging, and biologics container-closure systems all fall under characterization requirements. Therefore, manufacturers across multiple industries must understand and apply these principles.

Why the FDA Prioritizes Chemical Characterization

Patient safety is the FDA’s primary mandate. Chemical substances that migrate from device materials or pharmaceutical packaging into the body can cause toxicological harm. As a result, the agency requires robust chemical data before approving any product with patient-contact materials.

Moreover, regulatory submissions that lack rigorous chemical characterization face deficiency letters, clinical holds, or outright rejection. These outcomes cost manufacturers time and money. In addition, they delay patient access to potentially life-saving products. Proactive characterization prevents these outcomes.

Key Regulatory Frameworks Governing FDA Review

Several overlapping frameworks govern what the FDA expects in a chemical characterization submission. The most critical include:

• ISO 10993-18: Defines the chemical characterization process for medical device materials, including risk-based analytical approaches.
• FDA Guidance on Use of International Standard ISO 10993-1: Clarifies how the FDA interprets and applies ISO standards during device review.
• ICH Q3C, Q3D: Cover residual solvents and elemental impurities in pharmaceutical products, respectively.
• USP <232> / <233>: Provide limits and test methods for elemental impurities in drug products.
• FDA Guidance on Extractables and Leachables: Outlines E&L study expectations for drug containers and delivery systems.

Understanding which framework applies to your product category is essential. However, most submissions require elements from more than one guideline. Therefore, an integrated analytical strategy is always more effective than a siloed approach.

The FDA Chemical Characterization Review Process: Step by Step

The FDA chemical characterization review follows a structured, risk-based workflow. Manufacturers must plan this workflow carefully from the earliest design stage. Skipping steps or providing incomplete data are the most common causes of FDA deficiency letters in this area.

Step 1 — Material Identification and Risk Assessment

Every characterization study begins with a full inventory of materials used in the product. Notably, this includes polymers, metals, adhesives, coatings, lubricants, and colorants. Each material carries a unique chemical profile and a unique risk level based on patient contact duration and contact area.

Specifically, the FDA and ISO 10993-18 classify patient contact into three categories: limited (under 24 hours), prolonged (24 hours to 30 days), and permanent (over 30 days). Higher contact duration demands more exhaustive characterization. As a result, implantable devices require far more rigorous analysis than short-term external contact products.

Risk assessment at this stage also considers the biological endpoints of concern. These include cytotoxicity, sensitization, irritation, systemic toxicity, and carcinogenicity. Identifying relevant endpoints early helps analysts select the right analytical methods. Our Biocompatibility & Toxicity Testing service integrates seamlessly with chemical characterization at this stage.

Step 2 — Analytical Testing and Chemical Identification

After completing the risk assessment, laboratories perform the actual chemical testing. This phase involves identifying all chemical entities present above analytically relevant thresholds. Analysts use a suite of complementary techniques to achieve comprehensive coverage.

Common analytical techniques include:

• GC-MS (Gas Chromatography-Mass Spectrometry): Identifies volatile and semi-volatile organic compounds.
• LC-MS/MS (Liquid Chromatography-Tandem Mass Spectrometry): Detects non-volatile and polar extractables.
• ICP-MS (Inductively Coupled Plasma-Mass Spectrometry): Quantifies elemental impurities with parts-per-billion sensitivity.
• FTIR Spectroscopy: Confirms polymer identity and detects surface contaminants. See our FTIR Analysis service for details.
• XRD Analysis: Characterizes crystalline phases and inorganic compounds. Our XRD Analysis service supports this need.
• NMR (Nuclear Magnetic Resonance): Provides structural confirmation for unknown organic compounds.

Furthermore, extraction conditions must simulate real-world use. Analysts select solvents, temperatures, and contact times that reflect the worst-case clinical scenario. This approach ensures that the study captures all chemicals a patient could realistically encounter.

Step 3 — Quantification and Threshold Evaluation

Identifying a chemical is only half the task. Quantification determines whether detected substances exceed safety-based thresholds. The FDA and supporting guidance documents define several key thresholds:

Threshold Type	Definition	Action Required
Analytical Evaluation Threshold (AET)	Minimum level requiring chemical identification	Identify all compounds above AET
Qualification Threshold (QT)	Level above which toxicological qualification is needed	Conduct toxicological risk assessment
Reporting Threshold (RT)	Level above which reporting in submission is required	Report in regulatory dossier
Toxicological Concern Threshold (TTC)	Exposure level below which toxicological risk is negligible	May not require full toxicological assessment

Substances detected above the Qualification Threshold require a formal toxicological risk assessment. Consequently, this assessment becomes a key document in the FDA chemical characterization review submission. Our Chemical & Elemental Characterization service supports full quantification workflows aligned with these thresholds.

The Core of FDA Chemical Characterization Review: Extractables and Leachables

Extractables and leachables (E&L) studies represent the most technically demanding aspect of any FDA chemical characterization review. These extractables are chemicals that migrate from a material under controlled, often aggressive, laboratory conditions. By comparison, leachables are the subset of extractables that actually migrate into a drug product or patient under normal use conditions.

The distinction matters enormously. Extractables studies identify the universe of possible migrants. Leachables studies confirm which of those migrants actually appear in the final product or clinical environment. Therefore, both study types are typically required for a complete FDA submission.

Designing a Compliant E&L Study

Designing an E&L study requires careful selection of extraction solvents. Analysts typically use a polarity range — from aqueous to non-polar organic solvents — to capture chemicals with diverse solubility profiles. For example, common solvents include water, ethanol, isopropanol, and hexane.

In addition, extraction temperature and time must reflect worst-case clinical use. For example, a device used at body temperature for 30 days requires extraction conditions that simulate or exceed those parameters. Accelerated extraction protocols use elevated temperatures to condense long-duration exposure into shorter study timelines.

Moreover, analysts must validate the extraction method before relying on it for regulatory submission. Method validation confirms that the procedure is accurate, precise, specific, and reproducible. Our Method Development & Validation service provides fully documented validation packages that meet FDA and ICH expectations.

Analytical Techniques for E&L Studies

Comprehensive E&L studies use multiple orthogonal analytical techniques. No single method covers all chemical classes. Therefore, laboratories combine volatile organic analysis (GC-MS), non-volatile organic analysis (LC-MS), and elemental analysis (ICP-MS) to achieve full chemical coverage.

For polymer-based materials, FTIR Analysis confirms base polymer identity. This step ensures that no material substitution has occurred and that the correct chemical profile is being assessed. Furthermore, SEM Analysis can reveal surface morphology and particulate contamination that may not appear in solution-based studies.

Additionally, DSC Testing characterizes thermal transitions in polymer materials. These transitions can indicate the presence of plasticizers, additives, or processing residues that may subsequently leach. Combining thermal and chemical analysis gives a fuller picture of material behavior.

Quick Note: The FDA increasingly expects E&L data to be generated using methods validated under internationally recognized analytical standards. Unvalidated or legacy methods often trigger FDA information requests (IRs) during review. Always confirm method validation status before finalizing your study plan.

Leachables Confirmation and Safety Qualification

Once extractables are identified and quantified, scientists design a leachables confirmation study. Specifically, this study analyzes actual drug product or device eluates under simulated use conditions. Results confirm which extractables become real-world leachables.

Each identified leachable above the Qualification Threshold then undergoes a toxicological safety assessment. Toxicologists assign a Permitted Daily Exposure (PDE) or apply a Tolerable Intake (TI) value from established databases. Consequently, this process determines whether the detected leachable poses an unacceptable patient risk.

For complex or novel chemicals without established safety data, manufacturers may need to commission targeted toxicology studies. Research from PubMed Central – Trace Metals Review and peer-reviewed toxicology databases supports these assessments. Our Scientific & Technical Consulting team can guide manufacturers through this process efficiently.

Elemental Impurity Testing in FDA Chemical Characterization Review

Elemental impurity testing is a mandatory pillar of the FDA chemical characterization review for pharmaceutical products. Heavy metals and other elemental contaminants can accumulate in the body and cause serious harm, even at low concentrations. Therefore, regulators enforce strict limits on their presence in drug products and packaging.

ICH Q3D and USP <232>/<233> Requirements

ICH Q3D categorizes elemental impurities into three classes based on toxicity and likelihood of occurrence. Class 1 elements — arsenic, cadmium, lead, and mercury — pose the highest risk. Meanwhile, the Class 2 group covers cobalt, nickel, vanadium, and similar metals of moderate concern. By contrast, Class 3 elements carry relatively low toxicity but still warrant monitoring.

Furthermore, USP General Chapter <232> Elemental Impurities defines the permissible daily exposure (PDE) limits for each element by route of administration. These limits differ for oral, parenteral, and inhalation routes. Therefore, manufacturers must determine the correct PDE values for their specific product and route before designing their testing program.

ICP-MS as the Gold Standard Technique

ICP-MS is the preferred technique for elemental impurity quantification in regulatory submissions. It offers detection limits in the parts-per-trillion range, covering all ICH Q3D elements in a single analytical run. As a result, ICP-MS delivers comprehensive elemental data efficiently.

Our Chemical & Elemental Characterization service uses ICP-MS alongside ICP-OES for matrices that benefit from higher dynamic range. Together, these techniques cover all ICH Q3D elements with the sensitivity and accuracy regulators expect. In addition, our Chemical Purity & Contaminant Screening service adds a broader screening layer to catch unexpected impurities.

Pharmaceutical Packaging and Container-Closure Systems

Container-closure systems — including glass vials, rubber stoppers, plastic bottles, and prefilled syringes — are major potential sources of elemental contamination. Moreover, the FDA expects manufacturers to evaluate every patient-contact component for elemental migration potential.

Studies typically involve preparing aqueous and non-aqueous extracts of the packaging materials. Analysts then subject these extracts to ICP-MS analysis. Detected elements are compared against ICH Q3D PDE limits, adjusted for the daily dose of the drug product. Our Wet Chemistry & Classical Analytical Methods service supports sample preparation and digestion workflows for these matrices.

For solid dosage forms, analysts digest the drug product itself and analyze the digest for elemental content. This approach captures contributions from active pharmaceutical ingredients, excipients, and packaging alike. Consequently, the final risk assessment reflects the total elemental burden reaching the patient.

Analytical data quality is equally critical. Published research in Nature Reviews Methods Primers highlights how method performance directly affects the reliability of regulatory submissions. Therefore, all elemental methods used for FDA submissions must undergo full ICH Q2(R1) validation or at minimum a rigorous method qualification.

Our Chemical & Analytical Testing team routinely supports pharmaceutical clients through full elemental impurity testing programs, from study design through final report preparation for FDA submission.

Advanced Analytical Techniques Supporting FDA Chemical Characterization Review

Modern laboratories deploy a wide range of analytical techniques to meet FDA chemical characterization review expectations. Each technique targets a specific chemical class or concentration range. Consequently, combining multiple methods is always necessary for a complete regulatory dataset.

Atomic Spectroscopy: ICP-MS, ICP-OES, and AAS Compared

Three primary atomic spectroscopy methods support elemental analysis in regulatory submissions. In addition, understanding their strengths and limitations helps manufacturers select the right approach for each matrix.

Technique	Detection Range	Best Use Case	Regulatory Acceptance
ICP-MS	Parts-per-trillion (ppt)	Multi-element trace analysis; ICH Q3D compliance	Gold standard; fully accepted by FDA and USP
ICP-OES	Parts-per-billion (ppb)	Higher-concentration matrices; macro-element analysis	Widely accepted; often paired with ICP-MS
AAS (Atomic Absorption Spectroscopy)	Parts-per-billion (ppb)	Single-element focused studies; heritage methods	Accepted; less preferred for multi-element submissions
XRF (X-Ray Fluorescence)	Parts-per-million (ppm)	Rapid screening; solid materials and coatings	Screening only; requires ICP-MS confirmation

ICP-MS remains the dominant technique for FDA submissions because it measures all ICH Q3D target elements in a single run. However, ICP-OES complements ICP-MS when sample matrices contain high dissolved solids. Together, these techniques provide complete elemental coverage with confidence.

Chromatographic Methods for Organic Chemical Identification

Organic chemical characterization relies heavily on chromatography paired with mass spectrometry. GC-MS excels at detecting volatile and semi-volatile compounds, including residual solvents, plasticizers, and antioxidant degradation products. LC-MS/MS, meanwhile, handles non-volatile, polar, and thermally labile compounds that GC cannot resolve.

Furthermore, headspace GC-MS is particularly valuable for detecting trapped residual solvents in polymer materials. This technique analyzes vapors above a heated sample without solvent extraction. As a result, it avoids introducing new chemical interferences into the analysis.

High-resolution mass spectrometry (HRMS), including Orbitrap and Q-TOF platforms, adds another layer of power. HRMS enables accurate mass measurement and confident structure elucidation of unknown compounds. Consequently, HRMS is increasingly preferred for E&L studies where unknown leachables must be positively identified. Research published through ScienceDirect consistently highlights HRMS as a leading tool for trace-level organic characterization.

Microscopy and Surface Analysis Techniques

Chemical characterization is not limited to solution-based analysis. Surface and microscopy techniques reveal important information about material composition and particulate contamination. These methods often support or confirm findings from bulk chemical analysis.

Specifically, our SEM Analysis service uses scanning electron microscopy with energy-dispersive X-ray spectroscopy (SEM-EDX). This combination images surface features while simultaneously mapping elemental composition. Moreover, our TEM Analysis service provides nanoscale resolution for particle characterization in injectable drug products and biologics.

Together, these surface techniques create a comprehensive analytical picture. As a result, manufacturers submitting data for nanoparticle-containing products or complex implantable devices particularly benefit from this multi-technique approach.

Industry-Specific Applications of FDA Chemical Characterization Review

The FDA chemical characterization review applies across multiple regulated industries. However, each sector brings unique material types, patient contact scenarios, and regulatory pathways. Understanding industry-specific expectations helps manufacturers design efficient, targeted studies.

Medical Devices and Implantable Materials

Medical device manufacturers face some of the most demanding chemical characterization requirements. Implantable devices — such as orthopedic implants, cardiovascular stents, and neural stimulators — remain in patient contact permanently. Therefore, their chemical characterization must be exhaustive.

The ISO 10993-18 framework provides the primary roadmap for device chemical characterization. It mandates a risk-based analytical evaluation covering all device materials. Moreover, it requires manufacturers to justify the completeness of their analytical approach through a documented chemical characterization report (CCR).

Our Biocompatibility & Toxicity Testing service integrates directly with chemical characterization for device submissions. Biological endpoints — including cytotoxicity, genotoxicity, and carcinogenicity — are evaluated in the context of the identified chemical profile. This integrated approach satisfies FDA expectations under both ISO 10993-1 and ISO 10993-18.

Pharmaceutical Products and Drug Packaging

Pharmaceutical manufacturers must address chemical characterization at multiple levels. Active ingredients, excipients, manufacturing equipment, and primary packaging all require evaluation. Furthermore, the interaction between drug product and container-closure system is a critical area of FDA scrutiny.

Elemental impurity programs under USP Elemental Impurities guidance require risk assessments covering all potential elemental sources. These sources include water, raw materials, process equipment, and packaging components. Consequently, a comprehensive pharmaceutical program is a multi-step, cross-functional effort.

Our Chemical & Analytical Testing service supports pharmaceutical clients from early development through commercial manufacturing. We provide study design, method development, testing, and report writing — all aligned with FDA and ICH expectations.

Combination Products, Biologics, and Emerging Technologies

Combination products — such as prefilled syringes, drug-eluting stents, and autoinjectors — combine drug and device components in a single product. As a result, they fall under both pharmaceutical and device characterization requirements simultaneously. This dual applicability significantly increases the complexity of the chemical characterization program.

Biologics and biosimilars face additional challenges. Protein-based drugs are highly sensitive to leachables from container-closure systems. Even trace levels of extractables can cause protein aggregation or immunogenic responses. Therefore, the FDA demands especially rigorous E&L data for biologics submissions.

Our Scientific & Technical Consulting team helps manufacturers navigate these complex, multi-framework environments. We provide strategic regulatory consulting alongside analytical execution, ensuring that study designs address all applicable FDA expectations from the outset.

Quality Assurance Best Practices for FDA Chemical Characterization Review

Data quality is the foundation of a successful FDA chemical characterization review. Poorly executed studies — even with the right techniques — produce data that regulators cannot rely on. Therefore, rigorous quality assurance practices are non-negotiable in regulated analytical work.

Laboratory Accreditation and Good Laboratory Practice

Laboratories performing regulated analytical testing should hold ISO/IEC 17025 accreditation. Importantly, this accreditation confirms technical competence and management system compliance. Consequently, FDA reviewers can have confidence in data generated by accredited facilities.

Good Laboratory Practice (GLP) compliance is additionally required for certain non-clinical safety studies. GLP regulations govern study conduct, data integrity, and archiving. Furthermore, electronic data integrity — including audit trails and raw data preservation — is an increasing area of FDA inspection focus.

Quick Note: Laboratories that cannot demonstrate data integrity controls face significant regulatory risk. The FDA’s data integrity guidance requires that all analytical records be attributable, legible, contemporaneous, original, and accurate — known as the ALCOA principles. Always verify that your testing partner applies these principles before awarding work.

Method Validation and System Suitability

Every analytical method used in an FDA submission must be validated according to ICH Q2(R1) guidelines. Validation demonstrates that the method is accurate, precise, specific, linear, and robust. Unvalidated or partially validated methods are a leading cause of FDA information requests during review.

System suitability testing confirms that analytical instruments perform correctly on the day of analysis. Analysts run reference standards and acceptance criteria checks before every analytical sequence. As a result, any instrument drift or malfunction is caught before it affects sample data.

Our Method Development & Validation service delivers fully documented validation packages. These packages meet ICH Q2(R1), USP, and FDA expectations. Moreover, our validation reports include all raw data, statistical summaries, and acceptance criteria evaluations required for regulatory submission.

Documentation, Traceability, and Report Quality

Regulatory submissions live or die on documentation quality. Every analytical result must trace back to a calibrated instrument, a validated method, certified reference standards, and a qualified analyst. Consequently, this chain of traceability gives FDA reviewers the confidence to accept the data without further questions.

Chemical characterization reports must follow a logical structure. They should include scope, material descriptions, analytical methods, results, threshold comparisons, and a clear risk-based conclusion. Specifically, the conclusion must state whether each detected substance poses an acceptable or unacceptable risk to patients.

Our Chemical & Elemental Characterization service delivers report packages that meet FDA submission standards. In addition, our scientific team provides expert responses to FDA deficiency letters and information requests when needed.

Frequently Asked Questions About FDA Review of Chemical Characterization

What triggers an FDA chemical characterization review for a medical device?

Any medical device that contacts a patient — directly or indirectly — triggers characterization requirements. The extent of the review depends on contact type, duration, and the biological endpoints of concern. Permanent implants require the most comprehensive chemical characterization data packages.

How long does a complete E&L study typically take?

A complete extractables and leachables study typically takes between 12 and 24 weeks, depending on material complexity and the number of analytical techniques required. Accelerated extraction protocols can compress timelines for some product categories. However, biological endpoint studies and toxicological assessments add additional time on top of the analytical work.

Does the FDA accept ISO 10993-18 as sufficient for device chemical characterization?

The FDA generally accepts ISO 10993-18 as a foundational framework but applies its own additional guidance. Specifically, the FDA’s 2023 guidance on biocompatibility clarifies areas where it expects more detail than the ISO standard alone provides. Therefore, manufacturers should align studies with both ISO 10993-18 and the applicable FDA guidance documents simultaneously.

What is the difference between a screening study and a full characterization study?

A screening study identifies chemicals present above the Analytical Evaluation Threshold (AET) using a broad analytical sweep. A full characterization study goes further — it quantifies all identified substances, compares results against safety thresholds, and includes a formal toxicological risk assessment. Consequently, full characterization studies are required for regulatory submissions, while screening studies support early-stage development decisions.

Can manufacturers use existing literature data instead of generating new test data?

Manufacturers may use existing literature data, supplier data, or historical test results as supporting evidence. However, the FDA requires that any referenced data come from equivalent materials tested under equivalent conditions. Moreover, the agency often scrutinizes the vintage and validation status of legacy data. Therefore, new testing is almost always required for novel materials or new product configurations.

How does Materials Metric ensure its data meets FDA submission standards?

Materials Metric operates under ISO/IEC 17025 accreditation and applies ICH Q2(R1) method validation to all regulated testing. Our team includes analytical chemists, regulatory scientists, and toxicologists who collaborate on every project. Furthermore, we provide fully traceable reports with raw data, calibration records, and formal risk-based conclusions — all formatted for direct inclusion in FDA submissions.

Conclusion

The FDA chemical characterization review is a scientifically rigorous and regulatory-critical process. It demands comprehensive material identification, validated analytical methods, threshold-based risk assessment, and complete documentation. Consequently, manufacturers who invest in thorough chemical characterization early in development consistently experience smoother, faster regulatory submissions.

Moreover, the complexity of modern products — combination devices, biologics, nanoparticle formulations — continues to raise the analytical bar. Staying ahead of FDA expectations requires both technical expertise and regulatory awareness. As a result, partnering with an experienced, accredited laboratory is not a luxury — it is a strategic necessity.

Materials Metric provides end-to-end support for every stage of the FDA chemical characterization review process. From initial material risk assessment through E&L study design, elemental impurity testing, method validation, and final report preparation, our team delivers data that regulators trust. Every project benefits from our multi-technique analytical capabilities, our regulatory consulting expertise, and our commitment to data integrity.

Ready to build a stronger chemical characterization program? Contact Materials Metric today to discuss your specific product, timeline, and regulatory requirements. In addition, visit our service request page to start a project conversation with our analytical and regulatory science team. We are here to help you achieve regulatory confidence — efficiently and completely.

Related Posts from Materials Metric

Explore more insights from our team of materials scientists and analytical experts:

• Biological evaluation plan | Materials Metric | Compliance
• ISO 10993-1:2025 changes | Materials Metric | Compliance
• Trace Metal Analysis Services: Methods, Applications, and Regulatory Considerations
• Top Benefits of Choosing Materials Metric as Your Contract Research Organization

The post FDA chemical characterization review | Materials Metric appeared first on Comprehensive Materials Testing and Analytical Services at Materials Metric.